What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2024-04-01 compared with 2023-03-31 · 1250 added, 513 removed, 38 unchanged (98% of the section changed)

Technologies, Inc.

(the “Company,” “we,” or “our”) develops noninvasive, early-stage diagnostics

to detect and researches targeted therapies to detect and treat lung cancer and other diseases of the lung at the cellular level.

Company also is conducting early-stage research focused on advancing therapeutic discoveries that could result in broad-spectrum cancer

We develop proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets

cancer cells and cell populations indicative of a diseased state.

Company was formed as a Delaware corporation on March 26, 2014.

On June 15, 2016, we formed OncoSelect ® Therapeutics,

LLC, a Delaware limited liability company and wholly owned subsidiary of the Company.

Research and optimization of our platform technologies

are conducted in our laboratories at The University of Texas at San Antonio.

(the “Company,” “bioAffinity,” “we,” or “our”) develops noninvasive

diagnostics to detect early-stage lung cancer and other diseases of the lung.

We are advancing research into our therapeutic discoveries

which could result in broad-spectrum cancer treatments in the future.

We develop proprietary noninvasive diagnostic tests using flow

cytometry and automated analysis developed by artificial intelligence (“AI”).

Our diagnostic tests analyze cell populations,

including cancer and cancer-related cells, that are indicative of a specific diseased state.

were formed as a Delaware corporation on March 26, 2014.

On June 15, 2016, we formed OncoSelect ® Therapeutics, LLC (“OncoSelect ® ”) ,

a Delaware limited liability company and our wholly owned subsidiary which is a preclinical-stage biopharmaceutical discovery company

with a focus on therapeutics that deliver cytotoxic (cell-killing) effects on a broad selection of human cancers from diverse tissues

while having little or no effect on normal cells.

On August 14, 2023, we formed Precision Pathology Laboratory Services, LLC (“PPLS”),

a Texas limited liability company and our wholly owned subsidiary.

Research and optimization of our platform technologies for in vitro

diagnostics and technologies are conducted in laboratories at The University of Texas at San Antonio and PPLS in San Antonio, Texas.

first diagnostic test, CyPath ® Lung, addresses the need for noninvasive detection of early-stage lung cancer.

is the leading cause of cancer-related deaths.

Physicians are able to order CyPath ® Lung to assist in their assessment

of patients who are at high risk for lung cancer.

The CyPath ® Lung test enables physicians to more confidently distinguish

between patients who will likely benefit from timely intervention and more invasive follow-up procedures from patients who are likely

without lung disease and should continue annual screening.

CyPath ® Lung has the potential to increase overall diagnostic

accuracy of lung cancer, which could lead to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and

lower medical costs.

our wholly owned subsidiary, OncoSelect ® Therapeutics, LLC, our research has led to discoveries and advancement of novel

cancer therapeutics that specifically and selectively target cancer cells.

We are focused on expanding our broad-spectrum platform technologies

to continue developing tests that detect and therapies that target various types of cancer and potentially other diseases.

regarding the general development of bioAffinity’s business can be found in the “Business” section of our final IPO

prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the “Securities Act”)

on September 2, 2022 (the “Final Prospectus”) (see https://www.sec.gov/Archives/edgar/data/1712762/000149315222024949/form424b4.htm ).

is the leading cause of cancer-related deaths worldwide.

Physicians order CyPath ® Lung to assist in their assessment of

patients who are at high risk for lung cancer.

The CyPath ® Lung test enables physicians to more confidently identify patients

who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer

and should continue routine screening.

CyPath ® Lung has the potential to increase overall diagnostic accuracy of lung

cancer, which could lead to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics

indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

The flow cytometer is a well-established

instrument used in many commercial laboratories.

Flow cytometry collects data pertaining to properties of single cells labeled with antibodies

and dyes specific to cell types and characteristics.

Sputum is an excellent sample for analysis because it is in direct contact with

any malignancy in the lungs and can provide information about its area of field cancerization and the lung microenvironment.

Lung uses automated data analysis developed by AI that allows an entire sample of sputum averaging 16 million cells to be examined

in approximately 30 minutes, allowing for cost-effective, large-scale commercialization.

conducted a 150-patient test validation trial of people at high risk for lung cancer including patients with the disease (N=28) and those

who were cancer-free (N=122) that resulted in CyPath ® Lung’s overall 88% specificity, meaning the ability to correctly

identify a person without cancer, and 82% sensitivity, meaning the ability to correctly identify cancer in a person with the disease.

For the subset of patients in this trial who had lung nodules 20 millimeters (“mm”) or smaller, this trial resulted in 92%

sensitivity, 87% specificity, 99% negative predictive value, and 88% accuracy.

In this subset of 132 individuals with small nodules,

119 patients were cancer-free and 13 had confirmed lung cancer.

The detection of small lung nodules in people who have early-stage cancer

can increase lung cancer survival.

OncoSelect ® , our research has led to discoveries of novel potential cancer therapeutics that specifically and selectively

target cancer cells that have been grown in petri dishes.

September 2023, through our wholly owned subsidiary PPLS, we acquired the assets of Village Oaks Pathology Services, P.A.,(“Village

Oaks”) a Texas professional association d/b/a Precision Pathology Services, including a clinical anatomic and clinical pathology

laboratory and related services business in San Antonio, Texas.

The laboratory is accredited by the College of American Pathologists

(“CAP”) and certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”).

Direct Offering

March 6, 2024, we raised $2.5 million in gross proceeds from the sale to four institutional investors of (1) 1,600,000 shares of our

common stock (the “Shares”), par value $0.007 per share (“Common Stock”) in a registered direct offering, and

(2) warrants to purchase an aggregate of 1,600,000 shares of Common Stock (the “Common Warrants”) with an exercise price

of $1.64 in a concurrent private placement.

See “Management’s Discussion and Analysis of Financial Condition and Results

of Operations” for a more detailed discussion of this transaction.

Code Specific to CyPath ® Lung for Proprietary Laboratory Analyses

November 30, 2023, we announced that the Centers for Medicare and Medicaid Services (“CMS”) had made a final determination

for payment for CyPath ® Lung, our noninvasive test for early-stage lung cancer, for the 2024 calendar year.

January 1, 2024, CyPath ® Lung is on CMS’ 2024 clinical laboratory fee schedule.

The CPT Proprietary Laboratory Analyses

(“PLA”) code assigned to CyPath ® Lung is 0406U with the descriptor “Oncology (lung), flow cytometry,

sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung

Lung Branding

2023, we developed a series of marketing tools based on branding for CyPath ® Lung that emphasize our test’s

ability to assist physicians with next steps in patient care.

In January 2024, we began using the new marketing materials with both physicians

and patients.

The branding concepts were developed by the marketing and advertising firms of Havas Health & You, Trinity Life Sciences,

and K2MD to build the CyPath ® Lung brand and position it for success in the cancer diagnostics sector.

Passes CAP Inspection

January 11, 2024, PPLS successfully passed its bi-annual CAP inspection necessary for continuing operations.

CAP accreditation ensures

that laboratories meet the highest standards of quality and patient care under the Clinical Laboratory Improvement Amendments (CLIA),

including personnel qualifications, equipment, facilities, safety protocols, and overall management and quality of testing.

Platt, Ph.D., Joins Board of Directors

December 2023, Jamie Platt, Ph.D., Managing Director and Chief Executive Officer of Pictor Limited, where she is leading a turnaround

by restructuring and accelerating product development, joined the bioAffinity Technologies Board of Directors.

Platt has more than

two decades of experience bringing novel diagnostic technologies to global markets.

She was instrumental in merger and acquisition exits

for two diagnostic companies with a combined value of approximately $1 billion.

She previously was Chief Operating Officer of Personal

Genome Diagnostics which was acquired by LabCorp for $575 million.

We believe Dr.

Platt’s scientific acumen, business leadership,

and board experience will contribute to the Company’s growth and successful commercialization of CyPath ® Lung.

Bansal, M.D., Joins Medical and Science Advisory Board

February 2024, Sandeep Bansal, M.D., Medical Director of Pennsylvania’s Lung Innovations Network, joined our Medical and Scientific

Advisory Board.

Bansal is Board certified in pulmonary disease, critical care medicine and interventional pulmonology and has also

served as principal investigator of multiple clinical research trials and peer reviewer for several medical journals.

Lung Innovations

Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania,

incorporated CyPath ® Lung into its practice to aid in the detection of early-stage lung cancer in March 2024.

Bansal’s experience as both clinician and researcher is an important asset for bioAffinity Technologies.

of Department of Defense Research

the fourth quarter of 2023, we began selling CyPath ® Lung tests to the Department of Defense (DOD) to conduct an observational

study, “Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath ® Lung

Assay,” and for research and development on using bronchoalveolar lavage fluid as a biological sample to assess cardiopulmonary

function and exercise performance in military personnel post COVID-19 infection.

An additional research study was opened by Brooke Army

Medical Center in March 2023 to collect bronchoalveolar lavage samples to advance the research and development of a lung cancer test

to be used in conjunction with bronchoscopy to improve diagnostic accuracy with combined testing.

of Laboratory

September 18, 2023, PPLS consummated the acquisition of a clinical anatomic and clinical pathology laboratory and related services business

in San Antonio, Texas, pursuant to the terms of an Asset Purchase Agreement dated September 18, 2023, that we entered into with Village

Oaks Pathology Services, P.A., a Texas professional association d/b/a Precision Pathology Services, and Roby P.

PPLS is accredited

by the College of American Pathologists (“CAP”) and certified under the Clinical Laboratory Improvement Amendments of 1988

Founded in 2007 by Dr.

Joyce, the Medical Director and Laboratory Director of the clinical pathology laboratory

prior to and after the acquisition, has provided pathology services to physicians practicing in a variety of outpatient settings.

September 2021, Village Oaks, under the trade name Precision Pathology Services, has offered CyPath ® Lung for sale as

a laboratory developed test (“LDT”) for the detection of early-stage lung cancer.

In addition to CyPath ® Lung,

PPLS intends to continue to offer a range of laboratory services including respiratory testing for SARS-CoV-2 and influenza, anatomical

pathology, morphological stains, histological services, DNA extractions, STI testing, and women’s and men’s health testing.

to the terms of the Asset Purchase Agreement, PPLS acquired the laboratory assets, which included all of the assets owned by Village

Oaks other than medical assets, including the CLIA certification and CAP accreditation, which are assets Village Oaks used in connection

with its management and operation of a clinical pathology laboratory, now owned by PPLS, and related services business and assumed certain

liabilities and obligations.

Pursuant to the terms of the Asset Purchase Agreement, Village Oaks received $3,500,000 in consideration

for the assets to be purchased by PPLS, of which $1,000,000 was paid by the issuance of 564,972 shares of our restricted Common Stock

to a trust controlled by Dr.

Joyce which share number was determined by dividing $1,000,000 by $1.77, the average of the trading day

closing prices for the 30 days prior to September 15, 2023, rounded to the nearest whole share.

to the Asset Purchase Agreement, PPLS assumed all liabilities and obligations and obtained any and all rights, title and interest of

Village Oaks in and to (1) all leases for equipment and personal property related to the laboratory assets, pursuant to an Assumption

Agreement by and between Village Oaks and PPLS;

(2) certain other contracts related to the laboratory assets, including the license to

develop, manufacture, use, market, and sell CyPath ® Lung pursuant to the Assumption Agreement;

(3) all accounts payable

of Village Oaks as of September 18, 2023, that were incurred in the ordinary course of business consistent with past custom and practice;

and (4) the lease of the premises used in connection with operation of the CLIA-certified and CAP-accredited clinical pathology laboratory,

pursuant to an Assignment and Assumption of Lease by and between and PPLS.

connection with the Asset Purchase Agreement, PPLS entered into various other agreements, including a Management Services Agreement with

Village Oaks, a Succession Agreement with Village Oaks and Dr.

Joyce, and a Professional Services Agreement with Village Oaks pursuant

to which PPLS will provide comprehensive management and administrative services to Village Oaks in connection with the operation of its

professional cytopathology, histopathology, and clinical and anatomic pathology interpretation medical services practice.

PPLS will provide

space, equipment, administrative, management and clinical personnel, billing and collection, and related management services to Village

Oaks in exchange for a management fee of 70% of the net revenues received by Village Oaks from the provision of the medical services.

Succession Agreement provides that Dr.

Joyce, as holder of 100% of the issued and outstanding stock of Village Oaks, and Village Oaks

are restricted from disposing of their equity interests in Village Oaks, subject to certain exceptions, without the prior written consent

of us and Village Oaks.

to a Professional Services Agreement, Village Oaks provides pathology interpretation services as requested on behalf of PPLS based on

the professional fees approved for the CPT code for the services provided under the Medicare Physician Fee Schedule in the locality where

the test is performed.

connection with the Asset Purchase Agreement, we entered into an Executive Employment Agreement with Dr.

Joyce for a term of three years,

pursuant to which he serves as the Medical Director and Laboratory Director of PPLS, at a base salary of $333,333 per year.

to the Joyce Employment Agreement, Dr.

Joyce was also appointed to serve on our Board of Directors.

First Diagnostic Test – CyPath ® Lung

of the CyPath ® Lung Methodology

cancer is the leading cause of cancer-related death worldwide, claiming nearly 1.8 million lives annually.

1 Individuals

at high risk for lung cancer are recommended for annual screening by low-dose computed tomography (“LDCT”).

Apart from LDCT,

there is currently no reliable noninvasive method that can detect lung cancer at an early stage.

Our first diagnostic test, CyPath ®

Lung, is designed to be a cost-effective, 2 noninvasive, early-stage lung cancer diagnostic.

Using CyPath ®

Lung in conjunction with LDCT is predicted to improve the positive predictive value (the proportion of true positive results) by

a factor of five.

2 Improving the positive predictive value of LDCT with the use of CyPath ® Lung can result

in fewer patients unnecessarily subjected to invasive diagnostic procedures, earlier detection of lung cancer, and a reduction in healthcare

The Cancer Atlas, Third Edition, American Cancer Society (ACS), World Health Organization (WHO) and The Union for International Cancer

Control (UICC);

https://canceratlas.cancer.org/the-burden/lung-cancer/.

Analysis of the Potential Diagnostic, Patient and Economic Impact of CyPath® Lung When Used After

LDCT Screening to Detect Lung Cancer, bioAffinity Technologies Internal Analysis, 2022;

attached as Appendix I of the Company’s

Final Prospectus filed with the SEC on September 2, 2022, pursuant to Rule 424(b)(4) under the Securities Act (see https://www.sec.gov/Archives/edgar/data/1712762/000149315222024949/form424b4.htm ).

cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related deaths worldwide.

Globally, there were an estimated

2.21 million lung cancer cases and 1.8 million lung cancer deaths in 2020, as reported by the World Health Organization in its 2020 Cancer

According to the American Lung Association (“ALA”), screening for individuals at high risk for lung cancer has

the potential to improve lung cancer survival rates by finding disease at an earlier stage when it is more likely to be curable.

published in the New England Journal of Medicine titled “Survival of patients with stage I lung cancer detected on CT screening”

dated October 26, 2006, reported that the survival rate of individuals with Stage I lung cancer who underwent surgical resection within

one month after diagnosis had a ten-year survival rate of 92%, as compared to the overall five-year survival rate in the U.S.

as reported by the ALA.

Unfortunately, most lung cancer is detected in late stages.

The results of a large national clinical trial that

was reported in the New England Journal of Medicine in an article dated August 4, 2011, titled “Reduced Lung-Cancer Mortality

with Low-Dose Computed Tomographic Screening” showed that screening for lung cancer using low-dose computed tomography (“LDCT”)

resulted in a reduction of the mortality rate by 20% as compared to screening by X-ray if LDCT screening is used by patients at high

risk for lung cancer on an annual basis.

Therefore, LDCT scans are recommended for screening of an estimated 14 million Americans who

are at high risk for lung cancer.

If half of these high-risk individuals were screened, more than 12,000 lung cancer deaths could be

prevented, according to the ALA.

However, the New England Journal of Medicine article also reported that LDCT was shown to have

a low positive predictive value of less than 4%.

This means that for every 100 people who receive a positive result from LDCT screening

and are suspected of having lung cancer, only four actually have the disease.

A reliable, noninvasive, and cost-effective diagnostic

test can increase diagnosis of early-stage lung cancer while lowering the number of unnecessary and invasive procedures for patients

with a false positive result from LDCT screening.

(A false positive test result indicates that the patient has lung cancer when he or

she does not have the disease.)

Lung is a test for early-stage lung cancer that is designed to meet the need for greater diagnostic certainty.

Based on our internal

analysis, its use in conjunction with LDCT is predicted to improve the positive predictive value (the probability that patients with

a positive LDCT scan truly have the disease) by a factor of five.

Our analysis concludes that improving the positive predictive value

of LDCT with the use of CyPath ® Lung has the potential to subject fewer patients to the stresses of misdiagnosis or unnecessary

diagnostic procedures, such as biopsies, while also reducing healthcare costs.

Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics

1 unchanged sentence

The flow cytometer is a well-established

instrument used in many commercial laboratories that records properties of labeled and unlabeled single cells.

Sputum is an excellent

sample for analysis because it is in direct contact with any malignancy in the lungs and can thus provide a snapshot of the tumor itself,

its microenvironment, and its area of field cancerization.

While studies have shown that expert cytological analysis of sputum can detect

cancerous and pre-malignant cells, 4 the process of looking at microscopy slides is an extremely laborious approach and demands

years of expertise.

CyPath ® Lung uses flow cytometry and automated data analysis developed by artificial intelligence

(AI) that allows for an entire sample of sputum to be examined for cost-effective, large-scale screening or diagnosis.

particular, CyPath ® Lung uses a synthetic porphyrin called meso-tetra (4-carboxyphenyl) porphine

(“TCPP”), which is a naturally highly fluorescent porphyrin that has an unusually high affinity for cancer and

cancer-associated cells.

5 The uptake and retention of TCPP in cancerous tissue and its fluorescent properties make TCPP

an excellent bio-label for cancer.

As used in CyPath ® Lung, the proportion of cells with high TCPP fluorescence

intensity in a patient’s sputum sample is a significant predictor of lung cancer.

bioAffinity holds multiple patents

protecting its use of TCPP for the diagnosis, monitoring, and treatment of cancer.

In addition, the Company has multiple domestic

and foreign patent applications to protect the use of flow cytometry and its AI-developed automated analysis platform in the

detection of lung cancer and other lung diseases using sputum as a sample.

developed an algorithm using AI to distinguish samples from high-risk patients who had lung cancer from those who are cancer-free.

Pathology Services (“Precision Pathology”) developed CyPath ® Lung for sale as a Laboratory Developed Test

(an “LDT”) in accordance with the standards of the College of American Pathologists (“CAP”) and the regulations

and guidance of the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) program, which is administered by the Centers

for Medicare and Medicaid Services (“CMS”).

In developing the test as an LDT, Precision Pathology developed and integrated

software into the test protocol, which generated high-throughput and user-friendly, standardized analysis of flow cytometric sample data.

Our test can analyze an average sputum sample containing about 20 million cells in less than 20 minutes.

A physician’s report is

generated within minutes after data acquisition.

The test can be put into routine lab use without requiring expert evaluation of samples

or being subject to operator bias.

Our approach allows the entire sputum sample to be rapidly analyzed.

The numerical analysis developed

by AI captures complex interactions between lung cancer, the microenvironment, and areas of field cancerization that would be difficult

if not impossible for individuals to predict or detect reliably by eye.

For example, during test development, we discovered that viability

staining density suggests a link with apoptosis, or cell death, that is linked to many cancers, including lung cancer.

Our model also

suggests that specific markers of immune cell populations may be informative as to the presence of cancer in the lung.

These findings

are the result of our AI approach to automated analysis.

our knowledge, CyPath ® Lung is the first cancer diagnostic that combines automated flow cytometric analysis to predict

the presence of lung cancer from sputum samples.

Validation, Certification, and Classification of CyPath ® Lung

19-month test validation clinical trial of CyPath ® Lung 6 collected sputum noninvasively from people at high

risk for lung cancer, including patients with the disease (N=28) and those cancer-free (N=122).

Patients collected their sputum sample

over three days at home before bringing their sample to the clinical collection site.

Samples were shipped overnight to the laboratory

for analysis.

Study participants in the high-risk cohort had a CT to confirm they did not have lung cancer.

Those in the cancer cohort

had imaging and a biopsy that confirmed lung cancer.

After providing a sputum sample, participants were released from the study after

a physician either confirmed the individual was cancer-free by examination of CT imaging or confirmed the presence of lung cancer by

Flow cytometry and patient data used in analysis to produce the results included (1) the proportion of cells with a high ratio

of high TCPP fluorescence intensity over cell size;

(2) the proportion of cells with an intermediate ratio of fluorescence intensity

caused by the viability dye (FVS510) over cell size;

(3) the proportion of cells that were CD206 negative but positive for one or more

of the following markers:

CD66b (granulocytes), CD3 (T cells), and CD19 (B cells);

and (4) patient age.

Neumann, et al., Premalignant and Malignant Cells in Sputum

From Lung Cancer Patients, Cancer Cytopathology, Dec.

25, 2009, page 473-481.

El-Far MA, Pimstone N.

A comparative study of 28 porphyrins

and their abilities to localize in mouse mammary carcinoma:

instrument used in many commercial laboratories.

Flow cytometry collects data pertaining to properties of single cells labeled with antibodies

and dyes specific to cell types and characteristics.

Sputum is an excellent sample for analysis because it is in direct contact with

any malignancy in the lungs and can provide information about its area of field cancerization and the lung microenvironment.

While studies

have shown that expert cytological analysis of sputum can detect cancerous and pre-malignant cells, the level of scrutiny required for

the analysis is not feasible in the laboratory routine, according to an October 22, 2009, article, “Premalignant and malignant

cells in sputum from lung cancer patients,” published in Cancer Cytopathology .

The process of looking at microscopy slides

is an extremely laborious approach and demands years of expertise.

CyPath ® Lung uses flow cytometry and automated data

analysis developed by AI that allows for an entire sample of sputum averaging 16 million cells to be examined in approximately 30 minutes,

allowing for cost-effective, large-scale commercialization.

particular, CyPath ® Lung uses a synthetic porphyrin called meso-tetra (4-carboxyphenyl) porphyrin (“TCPP”).

Porphyrins are biological pigments that, when exposed to ultraviolet light at certain wavelengths, can result in the cell fluorescing

a red or purplish color that can be detected under a microscope or by flow cytometry, according to an article titled “Laboratory

Diagnosis of Porphyria,” published in Diagnostics (Basel) on July 26, 2021.

Porphyrins can be man-made, like TCPP, or they

can be naturally occurring, like heme that is responsible for the red color in red blood cells.

Cancer cells are known to take up certain

porphyrins in higher amounts than non-cancer cells, and the high affinity for cancer cells displayed by TCPP makes it an excellent bio-label

for cancer, according to an article published in Progress in Clinical and Biological Research in 1984 titled “A comparative

study of 28 porphyrins and their abilities to localize in mammary mouse carcinoma:

uroporphyrin I superior to hematoporphyrin derivative.”

Prog Clin Biol Res.

1984;170:661–672.

Lemieux, et al., Detection of Early-Stage Lung Cancer

in Sputum using Automated Flow Cytometry and Machine Learning.

2023;24(1):23.

10.1186/s12931-023-02327-3.

than half of those in the cancer cohort had lung cancer in the earlier Stages I-II.

The analysis, performed on an LSRII flow cytometer,

resulted in 92% sensitivity and 87% specificity in the subgroup of these patients (N=132) who had no nodules or lung nodules smaller

than 20 mm on their LDCT scan, while eight out of 10 (80%) of Stage I tumors were correctly identified.

Sensitivity is the percentage

of persons with the disease – in this case lung cancer – who are correctly identified by the test.

Specificity is the percentage

of persons without lung cancer who are correctly identified by the test.

The cancer group included all lung cancer types, but mostly

squamous cell carcinoma and adenocarcinoma lung cancer (in near equal numbers), showing that CyPath ® Lung detects all

types of lung cancer.

completion of the test validation trial, CyPath ® Lung was evaluated independently by Precision Pathology, which developed

the test for sale as an LDT in accordance with CAP/CLIA standards.

An LDT is a type of in vitro diagnostic (“IVD”)

test that is developed, validated, and performed within a single laboratory.

CyPath ® Lung has been validated and is being

performed by Precision Pathology, a CAP-accredited, CLIA-certified clinical pathology laboratory in San Antonio, Texas, pursuant to a

joint development agreement with the Company.

In third quarter 2022, Precision was inspected by CAP in accordance with CAP/CLIA regulatory standards and regulations

resulting in continued accreditation for the laboratory and the CyPath ® Lung test as an LDT.

part of CAP/CLIA certification, Precision Pathology evaluated the performance of CyPath ® Lung employing its own laboratory

technicians and a different flow cytometer, the Navios EX.

Results of Precision Pathology’s certification were comparable to those

from the test validation trial and demonstrated that CyPath ® Lung remains robust to differences in sample handling, processing,

and the type of flow cytometer.

Technologies intends to voluntarily seek FDA clearance of the CyPath ® Lung as a Class II IVD medical device for the detection

of lung cancer.

The Company has designed its pivotal trial with guidance from its clinical research organization (“CRO”),

Courante Oncology, and has prepared a pre-submission that will be submitted to the FDA for review and feedback.

We anticipate a three-year

diagnostic trial including an 18-month patient enrollment of approximately 1,800 patients, with participants followed for at least one

year after enrollment to determine whether they have lung cancer.

Similar to the test validation trial, the planned pivotal trial will

analyze flow cytometry and patient data including (1) the proportion of cells with a high ratio of high TCPP fluorescence intensity over

(2) the proportion of cells with an intermediate ratio of fluorescence intensity caused by the viability dye (FVS510) over

(3) the proportion of cells that were CD206 negative but positive for one or more of the following markers:

CD66b (granulocytes),

CD3 (T cells), and CD19 (B cells);

and (4) patient age.

Patient enrollment is scheduled to begin in 2023 at up to 20 collection sites.

Assuming the study is successful, we intend to submit a de novo classification request to the FDA within six months of study completion.

Patient- and Physician-Friendly CyPath ® Lung Process

Lung is designed to be noninvasive and patient friendly.

The diagnostic process uses sputum that is obtained noninvasively in the privacy

of a patient’s home.

Physicians order the test for their patients after lung cancer screening reveals a lung nodule considered

to be indeterminate because of the nodule size and lack of suspicious characteristics.

Lung nodules are considered indeterminate if their

size is between 6-20 mm in diameter.

Lung nodules of that size are associated with a lung cancer risk as low as 0.5% and up to 16%.

the CyPath ® Lung test, patients are given a small sample collection kit during an office visit with their physician.

Figure 1 below.) From the privacy of the patient’s home, the patient collects a sample of his or her sputum over three days using

a hand-held assist device that comes in the collection kit called an acapella ® Choice Blue made by Smiths Medical, which

acts to break up mucus in the patient’s lung and facilitates the patient’s ability to cough up sputum from the lung into

a collection cup that is also supplied with the kit.

In addition to the kit’s step-by-step instructions, an instructional video

and a live patient coach are available by calling 855-MYLUNGS to help patients with sample collection.

With the patient’s permission,

the patient coach will proactively call or text patients to offer assistance.

After the three-day sample of sputum is collected in the

collection cup, the patient puts the collection cup into the kit and uses a pre-addressed envelope provided in the kit to overnight the

sample to the laboratory.

Gierada et al;

https://pubmed.ncbi.nlm.nih.gov/25326638/.

the laboratory, the sputum is processed by technicians into a single-cell suspension and labeled with TCPP, which preferentially binds

to cancer cells and/or cancer-related cells.

Cells are also stained with fluorescently labeled antibodies that identify hematopoietic

and epithelial cells within the sputum sample.

A viability dye is used to eliminate dead cells.

The sputum sample is analyzed using flow

cytometry, which allows an average sputum sample containing about 20 million cells to be profiled in less than 20 minutes.

technician skilled in general laboratory techniques can accomplish sample processing, labeling, and data collection.

As used in CyPath ® Lung, the proportion of cells with high TCPP fluorescence intensity in a patient’s sputum sample

is a significant predictor of lung cancer.

We hold multiple patents protecting our use of TCPP for the diagnosis, monitoring, and treatment

In addition, we have multiple domestic and foreign patent applications to protect the use of flow cytometry and our AI-developed

automated analysis platform in the detection of lung cancer and other lung diseases using sputum as a sample.

developed an algorithm as part of a test validation trial that used machine learning to distinguish samples from high-risk patients who

had lung cancer from those who are cancer-free.

Results of the trial were published January 21, 2023, in the peer-reviewed journal Respiratory

Village Oaks developed CyPath ® Lung for sale as an LDT in accordance with the standards of the CAP and the

regulations and guidance of the CLIA program, which is administered by CMS.

Lung can be put into routine lab use without requiring expert evaluation of samples or being subject to operator bias.

allows the entire sputum sample to be rapidly analyzed.

The numerical analysis developed with machine learning captures complex interactions

between lung cancer, the microenvironment, and areas of field cancerization that would be difficult if not impossible for individuals

to predict or detect reliably by eye.

For example, during test development, we discovered that viability staining density suggests a

link with apoptosis, or cell death, that is linked to many cancers, including lung cancer.

Our model also suggests that specific markers

of immune cell populations may be informative as to the presence of cancer in the lung.

These findings are the result of our machine

learning approach to automated analysis.

Lung uses sputum that is obtained noninvasively by patients in the privacy of their home.

Physicians most often order the test

for patients after CT imaging reveals one or more pulmonary nodules that are suspected to be lung cancer.

A patient collects his or her

sample using a hand-held, noninvasive assist device, ICU Medical’s Acapella ® Choice Blue, that acts to break up

mucus in the lungs and help a person cough up sputum from the lung into a collection cup.

The Acapella ® Choice Blue has

been 510(k) cleared by the FDA as a positive expiratory pressure device to help mobilize lung secretions in people with certain lung

sputum sample is shipped overnight by the patient to PPLS and processed into a single-cell suspension, then labeled with antibodies that

distinguish different cell types and the synthetic porphyrin TCPP that identifies cancer cells and/or cancer-associated cells.

can analyze an average sputum sample containing about 16 million cells in approximately 30 minutes using integrated software for high-throughput,

user-friendly standardized analysis of flow cytometric sample data.

A physician’s report is generated within minutes after data

The report stratifies the patient into one of two risk groups.

Those patients deemed “likely or very likely”

to have cancer may benefit from aggressive intervention.

Those “unlikely or very unlikely” to have a malignancy may continue

imaging surveillance.

The physician also receives a numerical score between 0.1 to 1.0, with 0.1-0.49 being a negative result and 0.5

to 1.0 considered positive for lung cancer.

The proprietary automated analysis software was developed and is wholly owned and patent

protected by bioAffinity Technologies.

receive test results within three days after the laboratory receives the patient’s sputum sample.

4 unchanged sentences

decision to monitor this patient by following a recommended LDCT screening routine.

Patient- and Physician-Friendly CyPath ® Lung Process.

Lung Research and Clinical Studies

high affinity of TCPP for cancer and cancer-related cells and its fluorescent nature makes it an excellent bio-label for cancer.

CyPath ® Lung technology is based on this concept and scientific work originating at Los Alamos National Laboratory in

collaboration with St.

reported in an article titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning,”

published in Respiratory Research on January 21, 2023, we conducted a 150-patient test validation trial of people at high risk

for lung cancer including patients with the disease (N=28) and those who were cancer-free (N=122) that resulted in CyPath ®

Lung’s overall 88% specificity, meaning the ability to correctly identify a person without cancer, and 82% sensitivity, meaning

the ability to correctly identify cancer in a person with the disease.

For the subset of patients in this trial who had lung nodules

20 mm or smaller or no nodules at all, this trial resulted in 92% sensitivity, 87% specificity, 99% negative predictive value, and 88%

In this subset of 132 individuals with small nodules, 119 patients were cancer-free and 13 had confirmed lung cancer.

out of 10 (80%) of Stage I tumors were correctly identified.

Sensitivity is the percentage of persons with the disease – in this

case, lung cancer – who are correctly identified by the test.

Specificity is the percentage of persons without lung cancer who

are correctly identified by the test.

The cancer group included all lung cancer types, but mostly squamous cell carcinoma and adenocarcinoma

lung cancer (in near equal numbers), showing that CyPath ® Lung detects all types of lung cancer.

The detection of small

lung nodules in people who have early-stage cancer can increase lung cancer survival.

this 19-month test validation trial participants provided a sputum sample and were released from the study after a physician either confirmed

the individual was cancer-free by examination of CT imaging or confirmed the presence of lung cancer by biopsy.

Flow cytometry and patient

data used in the analysis produced results that included (1) the proportion of cells with a high ratio of high TCPP fluorescence intensity

over cell size;

(2) the proportion of cells with an intermediate ratio of fluorescence intensity caused by the viability dye (FVS510)

over cell size;

(3) the proportion of cells that were CD206 negative but positive for one or more of the following markers:

CD66b (granulocytes),

CD3 (T cells), and CD19 (B cells);

and (4) patient age.

CyPath ® Lung technology is based on scientific work originating at Los Alamos National Laboratory in collaboration with

Mary’s Hospital in Colorado.

A blinded clinical trial 8 (Patriquin, et.

al, 2015) of an earlier

version of CyPath ® Lung used a microscope to directly identify cells labeled with TCPP in one-third or less of the sputum

For each trial participant, researchers manually scanned 12 microscope slides labeled with TCPP for the presence of red fluorescing

cells (“RFCs”) displaying a spectral signature that indicated uptake of TCPP in the cell.

In addition to measuring the spectral

signature, the fluorescent intensity and cell size of RFCs were measured.

The test data, including fluorescent intensity over cell size,

was analyzed.

The Patriquin trial was conducted over 24 months and resulted in 81% test accuracy, 77.9% sensitivity, and 65.7% specificity

in the ability to correctly differentiate between samples from lung cancer patients and those at high risk who were cancer-free.

Patriquin trial required participants to provide a sputum sample and CT imaging of the lungs.

Those in the cancer cohort underwent a

biopsy to confirm lung cancer.

High-risk patients displaying indeterminate nodules were followed for 18 months to confirm they were cancer-free.

The Patriquin study concluded that optimizing the test to provide for analysis of the entire sputum sample would improve results.

Patriquin, et.al., Early detection of lung cancer with Meso-Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum, J Thorac Oncol.

2015;10(9):1311-1318.

10.1097/JTO.0000000000000627.

Company continued development of its lung cancer diagnostic technology culminating in a flow cytometry-based CyPath ® Lung

test incorporating automated AI analysis that evaluates the entire sputum sample.

A blinded diagnostic trial of the advanced test 9

(Lemieux, et al, 2023) resulted in 92% sensitivity and 87% specificity in the subgroup of these patients (N=132) who had no nodules

or lung nodules smaller than 20 mm on their LDCT scan, while eight out of 10 (80%) of Stage I tumors were correctly identified.

group included all lung cancer types, but mostly squamous cell carcinoma and adenocarcinoma lung cancer (in near equal numbers), showing

that CyPath ® Lung detects all types of lung cancer.

studies performed to date are summarized in the table below.

Lung Studies and Clinical Trials

localization and evaluation of cancer cell uptake of four different porphyrins

porphyrin localizes more than other porphyrins in cancer cells;

higher uptake of TCPP in cancer cells than in normal cells.

was determined by visual assessment.

Cell lines were used.

Researchers did not report the length of time taken to conduct this study,

nor any follow-up.

study to diagnose lung cancer by labeling sputum with TCPP and identifying red fluorescing cells under a microscope

of uranium miners (cancer N=8 / healthy N=4) that labeled sputum with TCPP resulted in 100% sensitivity and 100% specificity.

Classification

of cancer was made by subjective visual assessment of the presence and intensity of red fluorescing cells on slides.

In this blinded

study, one patient initially enrolled as a healthy subject was correctly diagnosed with cancer by the test.

Length of study not reported.

No patient follow-up was reported except for correct detection of cancer in patient initially enrolled as healthy.

validation study with microscopy-based assay completed to optimize TCPP labeling of sputum containing cancer and cancer-related cells

in lung cancer samples

this research study lasting eight months, the florescence intensity of TCPP-labeled cells in sputum was measured by subjective visual

assessment of microscope slides to distinguish samples from cancer and healthy cohorts.

Researchers who were blinded to sample origin

correctly identified samples from lung cancer patients (cancer N=15 / healthy N=12) resulting in 100% sensitivity and 100% specificity.

Participants were not followed up after providing the sputum sample and CT scan or biopsy.

Lemieux, et al.

Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.

2023;24(1):23.

10.1186/s12931-023-02327-3.

Detection of Lung Cancer with Meso-Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum 10

24-month clinical trial of 128 high-risk smokers and cancer patients used microscopy-based assay to identify TCPP-labeled cells in

sputum (cancer N=26 / high risk N=102) that resulted in 81% accuracy, 77.9% sensitivity, 65.7% specificity.

Slides were scanned.

Fluorescent intensity and cell size of RFCs were objectively measured by software.

High-risk participants who were cancer-free were

followed for 18 months to confirm status.

analysis by flow cytometry;

an effective platform to analyze the lung environment.

reporting on the CyPath ® Lung test’s quality controls included manual analysis of cell population data acquired

by flow cytometry analysis of sputum.

This research evaluated flow cytometry data from 164 participants’ sputum samples analyzed

manually for differences in cell characteristics, cell population size, and cell fluorescence intensity.

of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning 12

validation clinical trial using bioAffinity’s automated flow cytometry CyPath ® Lung test (cancer N=28 / high risk

N=122) resulted in overall 82% sensitivity and 88% specificity for the test;

CyPath ® Lung sensitivity is 92% and specificity

is 87% for patients with lung nodules smaller than 20 mm.

Porphyrin-modified

beads for use as compensation controls in flow cytometry 13

on the protocol for preparing porphyrin-labeled compensation beads invented by bioAffinity and used to optimize the results of CyPath ®

Lung test to detect early-stage lung cancer.

In the Los Alamos research study, sputum samples from lung cancer patients were differentiated

from non-cancer samples with 100% accuracy.

This early research was conducted with sputum from 12 uranium miners.

Microscope slides of

sputum samples were labeled with the synthetic fluorescent porphyrin TCPP.

The Los Alamos research study of 12 uranium miners included

eight men with cancer and four healthy individuals.

Researchers were blinded to the sample origin and looked for the presence of highly

fluorescent cells indicating uptake of TCPP as an indicator of lung cancer.

The length of the study and specific follow-up was not reported,

but researchers did report that one patient entering the study as a healthy subject was correctly diagnosed with cancer by the test.

Later, a blinded clinical trial was conducted and results published September 2015 in an article titled “Early Detection of Lung

Cancer with Meso-Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum” in the Journal of Thoracic Oncology .

This study reported

on an earlier version of CyPath ® Lung that used a fluorescent microscope to directly identify cells labeled with TCPP

in one-third or less of the sputum sample.

For each trial participant, researchers manually scanned 12 microscope slides labeled with

TCPP for the presence of red fluorescent cells (“RFCs”) displaying a spectral signature that indicated uptake of TCPP in

In addition to measuring the spectral signature, the fluorescent intensity and cell size of RFCs were measured.

The test data,

including fluorescent intensity over cell size, was analyzed.

The trial was conducted over 24 months and resulted in 81% test accuracy,

77.9% sensitivity, and 65.7% specificity in the ability to correctly differentiate between samples from lung cancer patients and those

at high risk who were cancer-free.

The Patriquin trial required participants to provide a sputum sample and CT imaging of the lungs.

Those in the cancer cohort underwent a biopsy to confirm lung cancer.

High-risk patients displaying indeterminate nodules were followed

for 18 months to confirm they were cancer-free.

The Patriquin study concluded that optimizing the test to provide for analysis of the

entire sputum sample would improve results.

January 1, 2024, the Medicare reimbursement code 0406U specific for CyPath ® Lung became effective after multiple regulatory

decisions in 2023 leading to approval.

On June 6, 2023, the American Medical Association (“AMA”) approved a Current Procedural

Terminology (“CPT”) Proprietary Laboratory Analysis (“PLA”) code specifically for use with CyPath ®

Lung, which was publicly released on June 30, 2023.

The new CPT code became effective for use on October 1, 2023.

On November 30, 2023,

we announced CMS’ final determination for payment for CyPath ® Lung, and CyPath ® Lung is on CMS’

2024 clinical laboratory fee schedule.

The CPT PLA code assigned to CyPath® Lung is 0406U with the descriptor “Oncology (lung),

flow cytometry, sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood

of lung cancer.”

have an agreement with GO2 Partners to produce patient collection kits and to provide warehousing and distribution services for sending

out the kits.

Laboratory reagents, supplies, and equipment are commercially available through multiple vendors.

Sample processing, labeling,

and data collection can be accomplished by a laboratory technician skilled in general laboratory techniques.

Data analysis leading to

a physician’s report is done by automated analysis software fully integrated into the test.

our knowledge, CyPath ® Lung is the first cancer diagnostic that combines flow cytometry and automated analysis to predict

the presence of lung cancer from sputum samples.

Cancer Diagnostics Market and CyPath ® Lung

global cancer diagnostic market is projected to grow from an estimated $102.24 billion in 2022 to $162.57 billion in 2030, with a compound

annual growth rate (“CAGR”) of 6.8%.

14 The market worldwide for lung cancer diagnostic tests was estimated at

$2.6 billion in 2022 and is projected to reach $4.7 billion by 2030, with a CAGR of 7.8% over 2022-2030.

15 bioAffinity Technologies

has the potential to play a significant role in the cancer diagnostic market because our platform is noninvasive, easy to use, cost-effective,

and has a potential to lead to better patient outcomes.

(See Analysis of the Potential Diagnostic, Patient And Economic Impact of

CyPath ® Lung When Used After LDCT Screening to Detect Lung Cancer, bioAffinity Technologies Internal Analysis with citations,

attached as Appendix I of the Company’s Final Prospectus filed with the SEC on September 2, 2022, pursuant to Rule 424(b)(4)

under the Securities Act) (see https://www.sec.gov/Archives/edgar/data/1712762/000149315222024949/form424b4.htm ).

Patriquin, et al.

Early Detection of Lung Cancer with Meso-Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum.

J Thorac Oncol.

2015;10(9):1311-1318.

10.1097/JTO.0000000000000627.

Bederka, et al.

Sputum analysis by flow cytometry;

an effective platform to analyze the lung environment.

PLoS One 2022;17(8).

10.1371/journal.pone.0272069.

Lemieux, et al.

Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.

2023;24(1):23.

10.1186/s12931-023-02327-3.

Bauta, et al., Porphyrin-modified beads for use as compensation controls in flow cytometry, Journal of Visualized Experiments (JoVE)

2023, CITATION

Research and Markets.

Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments), by Technology,

by Screening Type, by Application, by End-user, by Region, and Segment Forecasts, 2022-2030.

ResearchAndMarkets.com.

ReportLinker.

Global Lung Cancer Diagnostics Industry.

ReportLinker.com.

Lung is currently utilized as a diagnostic tool for detecting early-stage lung cancer.

bioAffinity is conducting research for the

expansion of its flow cytometric platform technology to detect and monitor lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma, and other cancers.

Company licensed CyPath ® Lung to Precision Pathology, which began marketing CyPath ® Lung in Texas as an

LDT in accordance with CAP/CLIA regulations pursuant to the terms of the joint development agreement between the Company and Precision

Limited funds were available to market CyPath ® Lung until the Company completed its IPO in September 2022.

CyPath ® Lung is sold to physicians who order CyPath ® Lung for patients at high risk for lung cancer after

an LDCT confirms the presence of lung nodule(s).

a front-end diagnostic tool used in conjunction with LDCT, the Company’s lung cancer test will help determine whether more expensive,

specialized, and/or invasive tests are warranted.

CyPath ® Lung compares favorably to current standards of care for diagnosing

lung cancer, including invasive biopsies, as seen in the table shown below.

annual growth rate (“CAGR”) of 6.1%, according to a market research report issued by Research and Markets in June

A January 2023 report, also by Research and Markets , stated that the market worldwide for lung cancer diagnostic tests was

estimated at $2.6 billion in 2022 and is projected to reach $4.7 billion by 2030, with a CAGR of 7.8% over 2022-2030.

We have the potential

to play a significant role in the cancer diagnostic market because our platform is noninvasive, cost-effective, and has the potential

to lead to better patient outcomes.

of CyPath ® Lung to Current Standards of Care

Diagnostic Test or

of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning,” published in Respiratory Research

on January 21, 2023

risk – nodules less than 20 mm

Dose CT screening 17

PET imaging ‌18

Bronchoscopy ‌19

of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning,” published in Respiratory Research

on January 21, 2023

of initial low dose computed tomographic screening for lung cancer,” published in the New England Journal of Medicine

on May 23, 2013

of FDG-PET to diagnose lung cancer in areas with infectious lung disease:

a meta-analysis,” published in JAMA in September

lung nodules – central lesions

collapsed/bleeding lung infection

Needle Biopsy 20

collapsed/bleeding lung infection

collapsed/bleeding lung;

bronchial genomic classifier for the diagnostic evaluation of lung cancer,” published in the New England Journal of Medicine

on July 16, 2015

needle biopsy

collapsed/bleeding lung infection

Rebel, VI, et al.

Automated Flow Cytometry Test Distinguishes

Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity, poster, 2020 World Conference on Lung Cancer.

January 2021.

National Lung Screening Trial Research Team, Church TR, Black

WC, Aberle DR, Berg CD, Clingan KL, et al.

Results of initial low dose computed tomographic screening for lung cancer.

N Engl J Med.

2013;368(21):1980-1991.

10.1056/NEJMoa1209120.

Deppen SA, et al.

Accuracy of FDG-PET to diagnose lung cancer

in areas with infectious lung disease:

a meta-analysis, JAMA.

2014;312(12):1227-1336.

10.1001/jama.2014.11488.

Silvestri GA, et al.

A bronchial genomic classifier for the

diagnostic evaluation of lung cancer.

N Engl J Med.

2015;373:243-251.

10.1056/NEJMoa1504601

Yao X, Gomes MM, Tsao MS, Allen CJ, Geddie W, Sekhon H.

collapsed/bleeding lung;

aspiration biopsy versus core-needle biopsy in diagnosing lung cancer:

a systemic review.

2012;19(1):e16-e27.

10.3747/co.19.871.

Zhang Y, Luo G, Etxeberria J, Hao Y.

Global patterns and trends

in lung cancer incidence:

a population-based study.

J Thorac Oncol.

2021;16:933–944.

bioAffinity’s

a systemic review,” published in Current Oncology

in February 2012

needle biopsy 21

collapsed/bleeding lung;

patterns and trends in lung cancer incidence:

a population-based study,” published in the Journal of Thoracic Oncology

on February 16, 2021

business model is to immediately address the need for a quick-to-market, noninvasive, cost-effective lung cancer diagnostic that will

save lives and reduce medical costs.

The Company is ready to capture a growing market.

Preventive Services Task Force recommended

doubling the number of Americans at high risk for lung cancer who are recommended for annual screening from 9 million to an estimated

China has an estimated 300 million smokers.

46 The European Union is estimated to have 34 million people at high

risk for lung cancer.

Following its entry into the U.S.

market, the Company expects to pursue CE marking of CyPath ® Lung

for sale in the European Union and is pursuing collaboration with a strategic partner to develop the test for the China market.

conducted market research with pulmonologists, oncologists, cardiothoracic surgeons, radiologists, and internists engaged in the diagnosis

and treatment of lung cancer to help assess these stakeholders’ reactions to the new diagnostic, CyPath ® Lung.

revealed a strong interest in CyPath ® Lung, driven by the high level of unmet clinical need for noninvasive diagnostics.

A survey conducted with 240 pulmonologists and internists, the primary audience for the test, showed that 96% would use CyPath ®

Lung if it were available today as an adjunct used for diagnosis after LDCT screening.

Physicians see the value of a noninvasive

diagnostic technology with the ability to confirm or rule out cancer and reduce the number of costly invasive procedures that result

from LDCT’s low positive predictive rate.

Preventive Services Task Force recommended new guidelines for screening in March 2021,

nearly doubling the number of Americans at high risk for lung cancer who are recommended for annual screening to 14 million people, according

In November 2023, the American Cancer Society updated its guidelines for lung cancer screening to include all former smokers

over the age of 50 regardless of when they quit, increasing the number of American adults eligible for screening to 19 million.

has an estimated 300 million smokers, according to the World Health Organization.

In Europe, it is estimated that there is one new case

of lung cancer diagnosed every minute, with incidence rates for males the highest in Eastern European countries and a five-year survival

rate of only 13%, as reported by a May 2021 article, “Lung cancer screening in Europe:

where are we in 2021?” published in

Translational Lung Cancer Research.

We expect to pursue CE marking of CyPath ® Lung for sale in the European Union.

conducted market research in the U.S.

with pulmonologists, oncologists, cardiothoracic surgeons, radiologists, and internists engaged

in the diagnosis and treatment of lung cancer to help assess their reactions to our diagnostic tool.

Research revealed a strong interest

in CyPath ® Lung, driven by the high level of unmet clinical need for noninvasive diagnostics.

A survey conducted with

240 pulmonologists and internists, the primary audience for the test, showed that 96% would use CyPath ® Lung if it were

available today as an adjunct used for diagnosis after LDCT screening.

Physicians responded favorably to a noninvasive diagnostic technology

that gives them more confidence in their decision to proceed with more aggressive follow-up procedures if the test comes back positive.

If test results are negative, physicians can rule out lung cancer, thus reducing the number of costly invasive procedures that result

from the LDCT false-positive rate.

Lung Business Development Plan

believe in the viability of the Company’s Business Plan based on the circumstances surrounding our business that are known to us

as of the date of this report.

However, the timing, strategies, and stages of our Business Plan may evolve in light of new circumstances

that cannot be predicted with certainty at this time.

Our Business Plan envisions four phases of expanding market entry into the U.S.,

the EU, and worldwide that are timed to maximize Company resources and minimize market risk.

Phase 1 of our Business Plan begins with

a controlled market launch of the Company’s LDT CyPath ® Lung in Texas followed by expansion into the Southwest market

Limited marketing was undertaken prior to the IPO that provided funds necessary to begin our controlled market launch.

2023, the Company announced that the marketing and advertising firms of Havas Health & You and Trinity Life Sciences had been engaged

to build the CyPath ® Lung brand and position it for success in the cancer diagnostics sector.

Havas Health & You,

the world’s largest global health network, is creating the branding and broader marketing strategy to align with the need for a

patient-friendly diagnostic that gives physicians another tool to assess the potential or presence of lung cancer in their high-risk

Trinity Life Sciences is providing advisory services, insights, and analytics to bioAffinity Technologies’ marketing

strategy for CyPath ® Lung.

The Company expects to begin a staged nationwide expansion of sales and marketing following

the successful completion of its controlled launch in 2023.

Phase 2 of our Business Plan anticipates entering the EU market with CyPath ®

Lung as a CE-marked IVD test with sales in the Netherlands, followed by a staged EU expansion.

Phase 3 of our Business Plan focuses

on the marketing of an FDA-cleared CyPath ® Lung test, beginning with a pivotal clinical trial in the U.S.

Phase 4 of our

Business Plan accelerates the market presence of CyPath ® Lung in countries in Asia, Eastern Europe, and Australia after

obtaining FDA marketing authorization in 2026.

each phase of commercialization, bioAffinity Technologies will develop messaging and marketing programs, including key convention attendance,

digital marketing, social media presence, and advertising, to create an “inbound” lead generation mechanism that delivers

our message to our target audience.

In addition, bioAffinity will collaborate with key opinion leaders (“KOLs”) to expand

our third-party reference and speaking pool of experts.

The Company will provide support and collateral materials, including posters,

presentations, videos, and peer-reviewed papers, to our KOLs who will present data and their experience with CyPath ® Lung

at key meetings.

This content can be shared across platforms, including websites and sales tools, and will be used as references to support

our product claims as well as sales and marketing efforts to physicians, reference laboratories, and patients.

We will also work with

lung cancer advocacy groups throughout all phases to support the message that routine screening can diagnose cancer at an early stage

and save lives.

believe in the viability of our business plan based on the circumstances surrounding our business that are known to us as of the date

of this Annual Report.

However, the timing, strategies, and stages of our business plan may evolve in light of new circumstances that

cannot be predicted with certainty at this time.

Our business plan envisions four phases of expanding market entry into the U.S., the

EU, and worldwide that are timed to maximize our resources and minimize market risk.

Phase 1 of our business plan has already begun with

a limited market launch of our LDT CyPath ® Lung in Texas.

This limited test market launch is designed to evaluate our

marketing program and help us ensure each step in the care pathway – from the initial order by physicians to sputum collection

and processing, to generating and delivering the patient report – is efficient and effective.

This limited test market approach

allows us to refine future positioning and develop strategic insight for our CyPath ® Lung test before expanding to a larger

believe that our strategy related to a limited market launch is proving successful.

On March 5, 2024, we reported accelerating growth

of 375% in CyPath ® Lung tests ordered and processed over from December 1, 2023, through February 29, 2024, as compared

to the prior three-month period.

We attribute the growth in sales to three 2023 initiatives that came to fruition early in 2024:

CMS’ inclusion of reimbursement for CyPath ® Lung on its 2024 clinical laboratory fee schedule;

(2) the hiring of

our new National Director of Sales, Dallas Coleman, who is experienced and well respected in the pulmonary field;

and (3) marketing materials

for the newly branded CyPath ® Lung that emphasize our test’s ability to assist physicians with next steps in patient

next step in our marketing plan is expansion into the Southwest market area in 2024 followed by a staged nationwide expansion of sales

and marketing beginning later in 2024.

In addition to introducing pulmonologists, family practitioners, and other providers to CyPath ®

Lung, we are selling CyPath ® Lung tests to the Department of Defense, which represents a significant potential market

for CyPath ® Lung.

Phase 2 of our business plan anticipates entering the EU market with CyPath ® Lung as

a CE-marked IVD test with sales in the Netherlands, followed by a staged EU expansion.

Phase 3 of our business plan focuses on the marketing

of an FDA-cleared CyPath ® Lung test, beginning with a pivotal clinical trial in the U.S.

Toward that end, we intend to

voluntarily seek FDA clearance of the CyPath ® Lung as a Class II IVD medical device for the detection of lung cancer.

We have designed our pivotal trial with guidance from our Clinical Research Organization (“CRO”), Courante Oncology, and

we are preparing a pre-submission that will be submitted to the FDA for review and feedback.

We anticipate a three-year diagnostic trial

including an 18-month patient enrollment of approximately 1,800 patients.

Similar to the test validation trial, the planned pivotal trial

will analyze flow cytometry and patient data including (1) the proportion of cells with a high ratio of high TCPP fluorescence intensity

over cell size;

(2) the proportion of cells with an intermediate ratio of fluorescence intensity caused by the viability dye (FVS510)

over cell size;

(3) the proportion of cells that were CD206 negative but positive for one or more of the following markers:

CD66b (granulocytes),

CD3 (T cells), and CD19 (B cells);

and (4) patient age.

Patient enrollment is scheduled to begin in 2024 at up to 20 collection sites.

Assuming the study is successful, we intend to submit a de novo classification request to the FDA within six months of study completion.

Phase 4 of our business plan accelerates the market presence of CyPath ® Lung in countries in Asia, Eastern Europe, and

Australia after obtaining FDA marketing authorization.

each phase of commercialization, we plan to develop messaging and marketing programs, including key convention attendance, digital marketing,

social media presence, and advertising, to create an “inbound” lead generation mechanism that delivers our message to our

target audience.

In addition, we plan to collaborate with key opinion leaders (“KOLs”) to expand our pool of third-party

experts and speakers.

We will provide support and collateral materials, including posters, presentations, videos, and peer-reviewed papers,

to our KOLs who will present data and their experience with CyPath ® Lung at key meetings.

This content can be shared across

platforms, including websites and sales tools, and will be used as references to support our product claims as well as sales and marketing

efforts to physicians, reference laboratories, and patients.

We will also work with lung cancer advocacy groups throughout all phases

to support the message that routine screening can save lives by diagnosing cancer at an early stage.

Competition for CyPath ® Lung

2022, we evaluated 67 companies advancing tests for the early detection of lung cancer that provided at least a scientific foundation

for their tests.

These competitors are investigating lung cancer screening and diagnostic methods that use various types of collected

samples (blood, breath, nasal epithelial cells, saliva, sputum, and urine) or imaging systems.

Of those 67 companies, we found that only

11 had conducted clinical studies in a manner and with results that could lead to further analysis.

The majority of these 11 tests are

in research and development, with only four tests on the market and one available to a limited number of medical centers.

Although CyPath ®

Lung was never tested directly against any of these five tests, comparison of the published performance numbers suggests CyPath ®

Lung might outperform them all.

(See Summary of Comparative Performance Analysis of Tests on the Market, bioAffinity Technologies

Internal Analysis, 2022 ;

attached as Appendix II of the Company’s Final Prospectus (see https://www.sec.gov/Archives/edgar/data/1712762/000149315222024949/form424b4.htm )).

the 67 companies we evaluated, we found only seven tests, including CyPath ® Lung, that represent a balanced test for early

lung cancer detection and that have advanced to the point that there is sufficient data for evaluation.

Of our six competitors with well-balanced

tests (two sell the same test;

one in the U.S.

and one in China), four companies (20/20 GeneSystems 48,49 ;

Savicell 51 ;

Visongate 52 ) conducted their studies on a population that does not match the high-risk population for

which the test is intended.

Their clinical data, therefore, is suspect as it applies to the population of patients who actually will

use the test.

The two remaining balanced tests are not on the market.

Lung has not been tested directly against its competitors’ products, but a comparison of the published performance numbers

suggests CyPath ® Lung is among the highest performing tests on the market.

Furthermore, CyPath ® Lung is

noninvasive – not even requiring a needle stick – and cost effective, and processing and analysis procedures are easy to

data and the results of clinical trials allow us to group lung cancer diagnostic tests into three categories:

(1) balanced tests;( 2)

rule-out tests, and (3) rule-in tests.

Balanced tests aim at excluding patients without cancer from unnecessary follow-up diagnostic

procedures and detecting patients with early-stage cancer who can proceed to more aggressive procedures to confirm diagnosis.

tests aim to exclude patients without cancer from unnecessary follow-up procedures with high accuracy (if the test provides a “negative”

result), but among the remainder of patients who do not receive an unambiguous negative result, there is still uncertainty about who

has cancer and who does not.

Cancer patients for whom time is of the essence are included in this group of patients still in uncertainty.

The patient can lose precious time with a rule-out test.

Rule-in tests aim to identify patients with cancer but in doing so may identify

many people without cancer as positive.

Therefore, rule-in tests have a low positive predictive value.

believe that balanced tests, like CyPath ® Lung, can be the most cost effective.

Those that perform well are most useful

to a physician and his or her patient because they provide the most information, allowing a quicker decision on what follow-up path to

whether to move forward with more aggressive follow-up procedures (i.e., in the case of CyPath ® Lung, if the test

reveals a “likely” or “highly likely” cancer result) or to follow a more conservative approach (i.e., when the

CyPath ® Lung test reveals an “unlikely” or “very unlikely” cancer result).

completed a competitive analysis in 2022 of 67 companies that published research sufficient to provide a scientific basis for evaluation.

We found only seven tests, including CyPath ® Lung, that represent a balanced test for early lung cancer detection and

have advanced to the point that there is sufficient data for evaluation.

One test is sold by two companies:

one from the U.S.

In the U.S., the test is called Lung LB (sold by LungLife AI) and is now on the market.

LungLB is a FISH-based test that

requires a significant amount of experience to conduct.

Four companies, each selling unique tests for early lung cancer detection, conducted

their studies on a population that does not match the high-risk population for which the test is intended.

Their clinical data, therefore,

is not necessarily representative of the results that would be achieved in the population of patients who actually will use the test.

The remaining balanced test, ProLung, is from IONIQ Sciences.

The test requires an expensive machine to measure transcutaneous bioconductance.

The test is not on the market at this time.

First Look was recently launched to assist in determining whether a person should be screened by LDCT.

While CyPath Lung ®

is positioned to help diagnose lung nodules in patients who have already undergone screening by LDCT, First Look is intended to be used

prior to LDCT.

As such, this test may increase lung cancer screening uptake and potentially increase the need for CyPath Lung ® .

found two rule-out tests on the market.

Both REVEAL, offered by MagArray, and Nodify-XL2, offered by Biodesix, are rule-out tests, meaning

the tests aim to exclude patients without cancer.

The REVEAL test is a blood test intended for patients with indeterminant nodules.

their 97-patient clinical validation trial, only patients with an intermediate risk of cancer, based either on a physician’s judgement

or a clinical model, took part.

This requirement led to 30% of high -risk patients being excluded at the onset of their analysis.

addition, the positive predictive value of the REVEAL test was 13.5% as compared to CyPath ® Lung’s positive predictive

value of 43.2%.

Importantly, no patients were excluded from the CyPath ® Lung test.

The tests had negative predictive values

of 98% and 97.8%, respectively.

The second rule-out test, Nodify-XL2, is used only by people with a pre-test probability of cancer less

As with the REVEAL test, a large number of patients were excluded from analysis.

In the case of Nodify-XL2, about 55% of patients

with lung nodules that physicians considered indeterminate, namely lung nodules sized between 8-30 mm, were excluded from the study.

In addition, Nodify XL-2 reported an AUC of 0.62 (unacceptable) and 0.76 (acceptable) for their two clinical trials, as compared to CyPath ®

Lung with an AUC of 0.89 and 0.90 in two independent study groups (excellent).

the Percepta nasal swab test offered by Veracyte is not widely available and is seeking a reimbursement code.

The test classifies patients

in low- and high-risk categories, or for those whose results are unclear, an intermediate category.

Test performance is different in

each risk category.

In a recently published paper of the test validation trial, the sensitivity and specificity for low-risk classification

was 97% and 40%, respectively, with those at low risk having an 8% calculated risk of having a malignancy.

The sensitivity and specificity

for the high-risk classification was 57% and 92%, respectively, and those patients who were put into the high-risk category had a 90%

risk of a malignancy.

One of the limitations of this study is that the participants in the validation trial had a cancer prevalence of

54% as compared to the overall high-risk population that has an estimated lung cancer prevalence of 1.1%, according to the National Lung

Cancer Screening Trial.

Therefore, we believe the nasal swab test’s performance may suffer when the classifier is tested on more

realistic cohorts with a cancer prevalence lower than 10%.

Although it is a patient-friendly test, a major limitation of the test is

that nearly half of all patients who took part in the validation trial could not be classified as either low- or high-risk;

they are considered “intermediate risk” with a 50:50 chance of having cancer.

Thus, in nearly half of the patients who received

the Percepta nasal swab test, the results would not help advance the diagnostic process.

In fact, for those patients in this indeterminate

category who do have cancer, valuable time in diagnosis may be lost.

believe there are many reasons why CyPath ® Lung is a superior test when compared to its competitors.

3 unchanged sentences

sputum contains immune cell populations in reaction to the presence of a tumor.

Second, bioAffinity’s proprietary technology is

straightforward.

bioAffinity’s CyPath ® Lung platform technology is not a molecular test and does not collect genetic

material that requires immediate processing.

CyPath ® Lung uses well-established flow cytometry techniques to investigate

cells contained in the sputum for characteristics that indicate whether cancer is present.

Sample processing is straightforward, and

laboratory technicians can be easily trained.

Second, our proprietary technology is straightforward.

Our CyPath ® Lung platform technology is not a molecular test and does not collect genetic material that requires immediate

CyPath ® Lung uses well-established flow cytometry techniques to investigate cells contained in the sputum

for characteristics that indicate the likelihood of lung cancer.

Sample processing is straightforward, and laboratory technicians can

be easily trained.

Reagents used by the test are widely available.

Data acquisition and analysis is fully

automated, allowing for efficient test results.

Third, CyPath ® Lung has shown high specificity and sensitivity that is

similar to far more invasive and more expensive procedures currently used to detect lung cancer.

Fourth, CyPath ® Lung

is cost effective.

Existing CPT cost codes that have a reimbursable track record have been identified for use with CyPath.

as important as any of our test’s benefits, CyPath ® Lung is patient friendly, providing at-home sample collection

that is noninvasive and offers particular benefit during a public healthcare crisis like the coronavirus pandemic.

a discussion of our competitors and competitive analysis, please see the “Business – The Competition for CyPath ®

Lung” section of our Final Prospectus (see https://www.sec.gov/Archives/edgar/data/1712762/000149315222024949/form424b4.htm ).

Research and Development

The Company is continuing its

research and development activities pertaining to diagnostics that include multiple studies we believe will support FDA final approval

of CyPath ® Lung, which we will seek after the pivotal trial is complete.

Our scientists also have begun preliminary studies

toward the development of CyPath ® Lung for detection of Chronic Obstructive Pulmonary Disease (COPD) and the assay’s

use with bronchoalveolar lavage fluid (BAL).

With regard to therapeutic research, the Company continues its experiments focused on establishing

proof-of-concept for our discovery that the silencing or knockdown of two genes that each encode a cell surface receptor results in cancer

death without much harm to healthy cells with the intent of advancing toward animal studies.

Data acquisition and analysis is fully automated, allowing for non-biased,

efficient test results.

Third, CyPath ® Lung has shown high specificity and sensitivity that is similar to far more invasive

and more expensive procedures currently used to detect lung cancer.

Fourth, CyPath ® Lung is cost effective, with a Medicare

reimbursement code billable to both government and private insurance carriers.

Fifth and as important as any of our test’s benefits,

CyPath ® Lung is patient friendly, providing at-home sample collection that is noninvasive and offers particular benefit

during a public healthcare crisis like the coronavirus pandemic.

and Development Activities

are continuing our research and development activities pertaining to diagnostics that include multiple studies we believe will support

FDA final approval of CyPath ® Lung, which we will seek after completing the pivotal trial.

With support from the DOD,

we are also conducting research advancing the development of CyPath ® Lung for detection of COPD and a test for use with

bronchoalveolar lavage fluid (BAL) as a companion test to bronchoscopy.

With regard to therapeutic research, we continue our experiments

focused on establishing proof-of-concept for our discovery that the silencing or knockdown of two genes that each encode a cell surface

receptor result in cancer death without perceived harm to healthy cells.

Diagnostic Applications for the CyPath ® Platform

expect to expand our platform technology to detect and monitor other lung diseases.

Our research is conducted, in part, in collaboration

with Brooke Army Medical Center in San Antonio, Texas, and partially funded by the DOD.

Obstructive Pulmonary Disease and Other Diseases of the Lung.

respiratory diagnostics market was valued at $5.6 billion in 2023 and is expected to reach $8.2 billion by 2029, according to a market

research study published by Research and Markets in November 2023.

The World Health Organization reports that COPD is the third

leading cause of death in the world, causing nearly 3.23 million deaths in 2019.

The disease is characterized as an abnormal inflammatory

response and airflow obstruction that cannot be fully reversed.

Early detection allows for the use of therapies when the disease is less

severe, which slows the progression of the disease.

We plan to build on our expertise in using sputum as a sample for flow cytometric

analysis to develop a test to detect COPD at an early stage and monitor for signs of impending exacerbations before clinical signs occur.

CyPath ® Lung’s flow cytometry platform provides for identification of cell populations and other parameters of disease

Our test illuminates the microenvironment of the lung.

We believe that our flow cytometric test can be designed to identify

other lung diseases, such as COPD and asthma, using antibodies that characterize cell populations in sputum specific to the disease.

Bronchoscopies.

market research firm Markets and Markets reports that the bronchoscopy market is primarily driven by an increasing prevalence of various

respiratory diseases such as COPD and lung cancer.

Improving reimbursement code policies, growing hospital investment in bronchoscopy

facilities, and technological advancements are factors driving growth of a market that was estimated at $2.5 billion in 2022 and expected

to reach an estimated $3.7 billion in 2027.

Despite advancements in bronchoscopy technologies, there remains a significant need for companion

tests that can increase diagnostic performance.

Bronchoscopy is considered minimally invasive but carries a risk of collapsed or bleeding

lung and risk of infection.

The sensitivity of bronchoscopy is 88% and specificity of 47%, according to the article “A bronchial

genomic classifier for the diagnostic evaluation of lung cancer” published in the New England Journal of Medicine on July

In collaboration with Brooke Army Medical Center, the CyPath ® process is being developed as a companion to bronchoscopy

in which samples are collected as part of the bronchoscopy process and processed using flow cytometry and automated analysis developed

Therapeutics Research

Therapeutics, LLC, a Delaware limited liability company and our wholly owned subsidiary, is a preclinical-stage biopharmaceutical

discovery company with a focus on therapeutics that deliver cytotoxic (cell-killing) effects on a broad selection of human cancers from

diverse tissues while having little or no effect on normal cells.

many of our industry competitors, OncoSelect ® does not pursue therapies that depend on specific mutations, biomarkers,

or other genetic or epigenetic abnormalities for their effect.

We pursue research based on our own scientific discoveries demonstrating

that inhibition of the expression of two specific cell membrane proteins results in the selective killing of various cancer cell types

grown in the laboratory with little or no effect on normal (non-cancerous) cells.

We have established several specific areas of therapeutic

research that offer the possibility of broad applications in cancer treatment.

OncoSelect ® will use a licensing business

model for selective chemotherapeutic compounds to be developed by the Company.

therapeutic platforms originated from our research on how TCPP, the synthetic porphyrin used in CyPath ® Lung, enters cancer

We conducted research to better understand the mechanism of TCPP’s selective uptake in cancer cells.

Our research identified

receptors, cell-membrane proteins which capture small molecules outside of the cell and bring them inside the cell, that are associated

Experiments that we conducted confirmed that at least two of these receptors, CD320 and LRP2, contributed to TCPP uptake by

cancer cells.

When these receptors were individually “knocked down” in cancer cells and therefore could not be made by the

cell, TCPP uptake was significantly decreased.

Knock-down of CD320 and LRP2 receptors was achieved by introducing siRNA molecules into

the cells that cause the destruction of CD320 and LRP2 gene products.

These gene products were the messenger (m)RNAs that are the precursors

of the receptor protein.

An siRNA is a small, chemically synthesized piece of RNA that specifically binds to mRNA, prohibiting the further

production of the corresponding proteins.

Thus, the reduction of CD320 or LRP2 mRNAs reduced the CD320 or LRP2 protein, respectively,

and resulted in decreased TCPP uptake in a variety of cancer cells, with a larger decrease observed when CD320 was knocked down.

We subsequently

discovered that the simultaneous knockdown of these two cell-surface receptors, CD320 and LRP2, was deadly to cancer cells or inhibited

their growth significantly but left normal cells virtually unharmed.

can be easily synthesized and are easily introduced into cells growing in a petri dish by a process called transfection.

been broadly adopted by academic and industrial researchers for the fundamental study of the function of genes and their proteins.

designed siRNAs to effectively eliminate CD320 and LRP2 protein production to study their role in TCPP uptake into the cell.

CD320 and LRP2 siRNAs, we achieved a reduction of CD320 and LRP2 protein levels of up to 90%.

Simultaneous siRNA knock-down of CD320

and LRP2 in normal cells, including skin fibroblasts and breast epithelial cells, did not affect cell growth.

However, knock-down of

CD320 and LRP2 in cancer cell lines derived from diverse tissues (lung, breast, prostate, brain, and skin cancers) inhibited cell growth

or killed the cells, in some cases up to 80%.

Interestingly, in some cell lines, when either CD320 or LRP2 were silenced individually,

a concurrent increase in protein expression of the other receptor was observed, suggesting that CD320 and LRP2 compensate for each other’s

hence, silencing both receptors is required for optimal cell killing.

These discoveries can lead to novel and very promising

therapeutic approaches for diverse cancers that do not appear to be dependent on any aberrant genetic or epigenetic profiles.

were incorporated in the State of Delaware on March 26, 2014.

Our principal executive office is located at 22211 West Interstate 10,

Suite 1206, San Antonio, Texas 78257, and our telephone number at that address is (210) 698-5334.

Our website address is https://www.bioaffinitytech.com/.

Information contained on or that can be accessed through our website is not incorporated by reference into this Annual Report.

should not consider any such information to be part of this Annual Report.

Property Portfolio

of March 31, 2023, the Company and its subsidiary OncoSelect have a patent estate that includes 14 issued U.S.

strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent

protection intended to cover our commercialized diagnostic test, pipeline product candidates and their use, as well as other inventions

that are important to our business.

In addition to patent protection, we also protect valuable company assets with copyright, trademark,

trade secret, and know-how through confidentiality agreements, invention assignment agreements, and a trade secret program to protect

aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

The confidentiality

agreements are designed to protect our proprietary information, and the invention assignment agreements are designed to gain company

control and ownership of technologies that are developed for us by our employees, consultants, or other third parties.

We seek to preserve

the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises, physical and electronic

security of our information technology systems, and non-disclosure agreements with those that produce or receive company confidential

While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies.

In addition, our trade secrets may otherwise become known or independently discovered by competitors.

commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important

technologies, inventions, and trade secrets related to our business, defend and enforce our intellectual property rights, particularly

our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual

property rights of others.

patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific, and factual issues.

In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be

reinterpreted and even challenged after issuance.

As a result, we cannot guarantee that any of our product candidates will be protectable

or remain protected by enforceable patents.

We cannot predict whether the patent applications we are currently pursuing will issue as

patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from

Any patents that we hold may be challenged, circumvented, or invalidated by third parties.

of April 1, 2024, we and our OncoSelect ® subsidiary have a patent estate that includes 16 issued U.S.

and foreign counterpart

patents including two U.S.

patents and twelve foreign counterpart patents in Australia, Canada, China, France, Germany, Hong Kong, Italy,

Mexico, Spain, Sweden, and the United Kingdom.

patent and nine counterpart foreign patents directed at diagnostic applications

expire in 2030.

Therapeutic patents registered in Australia, China Mexico and the U.S.

expire in 2037.

regard to our diagnostic test CyPath ® Lung and other diagnostic candidates, we have one issued U.S.

patent and nine foreign

counterpart patents in Canada, China, France, Germany, Hong Kong, Italy, Spain, Sweden, and the United Kingdom.

With regard to our diagnostic

patent applications, one family is directed at diagnosing lung health using flow cytometry, and the other family is directed at proprietary

compensation beads used to calibrate the flow cytometry instrument and used in CyPath ® Lung data acquisition.

applications directed at diagnosing lung health include one pending U.S.

non-provisional patent application and eight foreign counterpart

patent applications in Australia, Canada, China, European Patent Office, Hong Kong, Japan, Mexico, and Singapore filed in 2019, one Patent

Cooperation Treaty (PCT) International Application directed to the composition of compensation beads and one PCT International Application

directed to diagnosing lung health using flow cytometry were filed in 2022.

patents and 14 foreign counterpart patents in Australia, Canada, China, France, Germany, Hong Kong, India,

Italy, Mexico, Spain, Sweden, and the United Kingdom.

We and OncoSelect ® own all patents and trademarks in our intellectual

property portfolio.

patent and nine counterpart foreign patents directed at diagnostic applications expire in 2030.

patent and five counterpart foreign patents directed at therapeutic applications expire in 2037.

regard to our diagnostic patent portfolio, we have one issued U.S.

patent and nine foreign counterpart patents in Canada, China, France,

Germany, Hong Kong, Italy, Spain, Sweden, and the United Kingdom.

With regard to our diagnostic patent applications, there are two families

of which one is directed at diagnosing lung health using flow cytometry and the other is directed at proprietary compensation beads used

in analysis by flow cytometry.

The diagnostic family of pending patent applications is directed at diagnosing lung health and includes

one pending non-provisional U.S.

patent application and eight foreign counterpart patent applications in Australia, Canada, China, European

Patent Office, Japan, Hong Kong, Mexico, and Singapore filed in 2019, one International Patent Application filed in 2022 and one International

Patent Application filed in 2023.

Also, a patent application directed at the composition of compensation beads was filed as an International

Patent application in 2022.

regard to our therapeutic product candidates, we have one issued U.S.

patent, two pending U.S.

patent applications, three issued foreign

patents, ten foreign applications pending in Canada, China, European Patent Office, Hong Kong, India, and Japan and one pending PCT International

Application,.

The therapeutic intellectual property is made up of four families directed at our therapeutic product candidates, including

two families directed at siRNA product candidates, one family directed at soluble CD320 used in the treatment of cancer, and one family

directed at porphyrin conjugates for treating cancer.

a discussion of the extensive government regulation that the Company and our IVD medical device, CyPath ® Lung, are subject

to, please see the “Business – Government Regulation” section of our Final Prospectus (see https://www.sec.gov/Archives/edgar/data/1712762/000149315222024949/form424b4.htm ).

Company places significant emphasis on the recruitment, development, and retention of its employees who include award-winning scientists

dedicated to advancing scientific discovery from bench to bedside.

Of the Company’s 14 employees, all of whom are employed full-time

by the Company, one holds an MD and seven hold PhDs in biology or medicinal chemistry.

Approximately nine employees are engaged in research

and development and approximately five in sales or general administration.

Executive Vice President and Chief Medical and Science Officer, Vivienne Rebel, holds an MD and PhD.

Business development is led by our

Vice President of Operations, Xavier Reveles, who has 25 years of experience as a clinical geneticist skilled in the creation and management

patent, five issued foreign patents in Australia, China, Hong Kong,

India and Mexico, two pending U.S.

applications, and 10 foreign applications pending in Canada, China, European Patent Office, Hong Kong,

India, and Japan and one pending International Patent Application filed in 2022.

The therapeutic intellectual property is made up of

two families, including one family directed at our siRNA product candidates for the treatment of cancer, and another family directed

at our porphyrin conjugates for treating cancer.

One therapeutic patent application has been granted in China that expires in 2037.

term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.

In most countries

in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.

In the U.S., the

term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation

for the loss of patent term during the FDA regulatory review process.

The period of extension may be up to five years beyond the expiration

of the patent, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval.

patent among those eligible for an extension may be extended, and a given patent may only be extended once.

Similar provisions are available

in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug.

It is possible that issued

patents covering each of our therapeutic product candidates may be entitled to patent term extensions.

If our product candidates

receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved

product candidates.

We also intend to seek patent term extensions in any jurisdictions where they are available;

however, there is no

guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted,

and, if granted, the length of such extensions.

addition to patent protection, we also rely on know-how and trade secret protection for our proprietary information that is not amenable

to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position.

However, trade secrets

can be difficult to protect.

Although we take steps to protect our proprietary information, including restricting access to our premises

and our confidential information, as well as entering into agreements with our employees, consultants, advisors, and potential collaborators,

third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information.

As a result, we may be unable to meaningfully protect our know-how, trade secrets, and other proprietary information.

addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities.

Products (including Medical Devices and Tests)

the U.S., medical devices, including IVDs are subject to extensive regulation by the FDA, under the federal Food, Drug and Cosmetic

Act (“FDCA”) and its implementing regulations, and certain other federal and state statutes and regulations.

and regulations govern, among other things, the design, manufacture, storage, recordkeeping, approval, labeling, promotion,

post-approval monitoring and reporting, distribution, and import and export of medical devices, including IVDs.

IVDs are a category

of medical device that can be purchased by clinical laboratories and used to perform laboratory testing.

IVDs include reagents and

instruments used to detect the presence of certain chemicals or other biomarkers in human specimens for the purpose of diagnosis or

detection of diseases or conditions.

IVDs can also be used to perform predictive, prognostic, and screening testing.

medical devices, IVDs may require premarket review and clearance, authorization, or approval by the FDA.

Failure to comply with

applicable requirements may subject a device and/or its manufacturer to a variety of administrative and judicial sanctions, such as

FDA refusal to approve pending premarket approval (“PMA”) applications, issuance of warning letters or untitled letters,

mandatory product recalls, import detentions, civil monetary penalties, and/or judicial sanctions, such as product seizures,

injunctions, and criminal prosecution.

Developed Tests

Lung has entered the U.S.

market as an LDT.

The FDA considers LDTs to be tests that are developed, validated, and performed within

a single laboratory.

While CMS oversees clinical laboratory operations through the CLIA program, the FDA has the authority to regulate

LDTs as IVDs under the FDCA but has generally exercised enforcement discretion with regard to LDTs.

This means that even though the FDA

believes it can impose IVD regulatory requirements on LDTs, such as requirements to obtain premarket approval, authorization, or clearance,

it has generally chosen not to enforce those requirements except in cases it deemed appropriate to address significant public health

September 2023, the FDA announced a proposed rule to ensure the safety and effectiveness of LDTs by amending regulations to explicitly

say that IVDs offered as LDTs fall under the FDCA and phase out its general enforcement discretion approach for most LDTs.

policy makes it clear that the FDA intends to provide greater oversight of LDTs.

The FDA plans to finalize its ruling in April 2024 and

initiate a phased implementation process in which it will require laboratories to register their LDTs and begin the premarket review

process over the next four years.

2021, two bills were reintroduced in the U.S.

the Verifying Accurate, Leading-edge IVCT Development Act of 2020 (the “VALID

Act”), which would have expressly granted the FDA authority to regulate LDTs under a risk-based framework;

and the Verified Innovative

Testing in American Laboratories Act of 2020 (the “VITAL Act”), which would have assigned LDTs to regulation solely under

CLIA and would have directed CMS to update its CLIA regulations.

Neither of these bills were enacted.

The VALID Act was reintroduced

in March 2023.

The likelihood that Congress will pass the VALID Act, VITAL Act, or similar legislation, and the extent to which such

legislation may affect the FDA’s plans to regulate LDTs as medical devices is difficult to predict.

Laboratory Improvement Amendments of 1988

laboratories testing specimens collected in the U.S.

for the purpose of disease diagnosis or health assessment are subject to CLIA, unless

CLIA establishes quality standards for all clinical laboratory testing to ensure the accuracy, reliability, and timeliness of

patient test results regardless of where the test was performed.

In particular, these regulations mandate that clinical laboratories

must be certified by the federal government or an accreditation organization with deemed status from the federal government, or must

be located in a state that has been granted exemption from CLIA requirements because the state has laws in effect that provide for requirements

equal to or more stringent than CLIA requirements.

CLIA also requires that laboratories meet quality assurance, quality control and personnel

standards, perform proficiency testing, and undergo inspections.

The CLIA standards applicable to clinical laboratories are based on

the complexity of the testing performed by the laboratory, which ranges from “waived” to “moderate complexity”

to “high complexity.” In the case of tests performed using IVDs, test complexity categorization of the IVD is performed by

is a member-based physician organization comprising approximately 18,000 board-certified pathologists.

CAP’s Laboratory Accreditation

Program has been granted deeming authority from the federal government, meaning that CAP accreditation can be used to qualify for CLIA

certification and to satisfy CLIA inspection requirements.

FDCA classifies medical devices into one of three categories based on the risks associated with the device and the level of control necessary

to provide reasonable assurance of safety and effectiveness.

Class I devices are low risk and are subject only to general regulatory

Class II devices are moderate risk.

They are subject to general controls and may also be subject to special controls.

III devices are generally the highest risk devices.

They are required to obtain premarket approval and comply with postmarket conditions

of approval in addition to general regulatory controls.

establishments that design and/or manufacture devices are required to register their establishments with the FDA.

They also must provide

the FDA with a list of the devices that they design and/or manufacture at their facilities.

FDA enforces its requirements by market surveillance and periodic inspections, both announced and unannounced, to review records, equipment,

facilities, laboratories, and processes to confirm regulatory compliance.

These inspections may include the manufacturing facilities

of subcontractors.

Following an inspection, the FDA may issue a report, known as a Form 483 notice of observations, listing instances

where the manufacturer has failed to comply with applicable regulations and/or procedures.

The FDA may also issue a public warning letter.

If the manufacturer does not adequately respond to a Form 483 or warning letter, the FDA may take enforcement action against the manufacturer

or impose other sanctions or consequences, which may include:

and desist orders;

or consent decrees;

monetary penalties;

detention, or seizure of products;

restrictions, partial or total shutdown of production facilities;

of or delay in granting requests for 510(k) clearance, de novo classification, or premarket approval of new products or modified

510(k) clearances, de novo classifications, or premarket approvals that are already granted;

to grant export approval or export certificates for devices;

Authorization and Notification

most Class I and some Class II devices may be marketed without prior FDA authorization, many Class II and most Class III medical devices

can be legally sold within the U.S.

only if the FDA has:

(1) approved a PMA application prior to marketing, generally applicable to most

Class III devices;

(2) cleared the device in response to a premarket notification (a “510(k) submission”), generally applicable

to some Class I and most II devices;

or (3) authorized the device to be marketed through the de novo classification process, generally

applicable for novel low- or moderate-risk devices.

PMA applications, 510(k) premarket notifications, and de novo requests require

payment of user fees.

Premarket Notification

marketing in the U.S.

for most Class II and a limited number of Class I devices typically follows the 510(k) premarket notification pathway.

To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially

equivalent to a legally marketed device, referred to as the “predicate device.” A predicate device may be a previously 510(k)

cleared device or a Class III device that was in commercial distribution before May 28, 1976, for which the FDA has not yet called for

PMA applications, or a product previously placed in Class II or Class I through the de novo classification process.

The manufacturer

must show that the proposed device has the same intended use as the predicate device, and that it either has the same technological characteristics,

or has different technological characteristics but is shown to be equally safe and effective and does not raise different questions of

safety and effectiveness as compared to the predicate device.

FDA has a user fee goal to apply no more than 90 calendar review days to 510(k) submissions.

During the process, the FDA may issue an

Additional Information request, which stops the clock.

The applicant has 180 days to respond, although during the COVID-19 Public Health

Emergency, the FDA has permitted companies an additional 180 days in which to respond.

Therefore, the total review time absent the Public

Health Emergency could be up to 270 days, and in practice may be longer.

a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute

a major change in its intended use, requires a new 510(k) clearance or could require a PMA approval or de novo classification.

The FDA requires each manufacturer to make this determination in the first instance, but the FDA can review any such decision.

FDA disagrees with a manufacturer’s decision not to seek a new 510(k) clearance for the modified device, the agency may retroactively

require the manufacturer to seek 510(k) clearance, de novo classification, or PMA approval.

The FDA also can require the manufacturer

to cease marketing and/or recall the modified device until 510(k) clearance or PMA approval is obtained.

Novo Classification

of a new type that the FDA has not previously classified based on risk are automatically classified into Class III regardless of the

level of risk they pose.

To avoid requiring PMA review of novel low- to moderate-risk devices classified in Class III by operation of

law, Congress enacted a provision that allows the FDA to reclassify a novel low- to moderate-risk device into Class I or II in the absence

of a predicate device that would support 510(k) clearance.

The FDA evaluates the safety and effectiveness of devices submitted for review

under this de novo pathway and devices determined to be Class II can serve as predicate devices for future 510(k) applicants.

The de novo pathway can require clinical data.

FDA has a user fee goal to review a de novo request in 150 calendar review days.

During the process, the FDA may issue an Additional

Information request, which stops the clock.

The applicant has 180 days to respond.

Therefore, the total review time could be as long

as 330 days and in practice may be longer.

During the COVID-19 public health emergency, applicants were given an additional 180 days

in which to respond.

Class III product generally must follow the PMA approval pathway.

The PMA must be supported by sufficient valid scientific evidence,

including clinical study data, to assure that the device is safe and effective for its intended use(s).

After completion of clinical

testing, a PMA including the results of all non-clinical, clinical, and other testing and information relating to the product’s

marketing history, design, labeling, manufacture, and controls, is prepared and submitted to the FDA.

PMA approval process is generally more expensive, rigorous, lengthy, and uncertain than the 510(k) premarket notification process and

de novo classification process and requires proof of the safety and effectiveness of the device to the FDA’s satisfaction.

As part of the PMA review, the FDA will typically inspect the manufacturer’s facilities for compliance with Quality System Regulation

(“QSR”) requirements, which impose elaborate testing, control, documentation, and other quality assurance procedures.

FDA has a user fee goal to review a PMA in 180 calendar review days if the submission does not require advisory committee input, or 320

review days if the submission does require advisory committee input.

During the process, the FDA may issue a major deficiency letter,

which stops the review clock.

The applicant has up to 180 days to respond.

Therefore, the total review time could be up to 360 days,

if the submission does not require advisory committee input, or 500 days if the submission does require advisory committee input, and

in practice may be longer.

The COVID-19 pandemic significantly increased the FDA’s workload because of the need to review emergency

use authorization requests for IVDs and other regulated products, which delayed review timelines for some non-COVID-19 products.

the FDA’s evaluation of the PMA application is favorable, the FDA will issue a PMA for the approved indications, which can be more

limited than those originally sought by the manufacturer.

The PMA can include post-approval conditions that the FDA believes necessary

to ensure the safety and effectiveness of the device including, among other things, restrictions on labeling, promotion, sale, and distribution

or a requirement for postmarket surveillance or completion of postmarket studies.

Failure to comply with the conditions of approval can

result in material adverse enforcement action, including the loss or withdrawal of the approval and/or placement of restrictions on the

sale of the device until the conditions are satisfied.

after approval of a PMA, a new PMA or PMA supplement may be required in the event of a modification to the device, its labeling, or its

manufacturing process.

Supplements to a PMA may require the submission of the same type of information required for an original PMA,

except that the supplement is generally limited to that information needed to support the proposed change from the product covered by

the original PMA.

at least one clinical trial is required to support a PMA application.

Clinical studies also may be required for de novo classification

or a 510(k) premarket notification.

Clinical trials may also be conducted or continued to satisfy post-approval requirements for devices

For significant risk investigational device studies, the FDA regulations require that human clinical investigations conducted

be subject to an approved investigational device exemption (“IDE”).

An IDE application is considered approved

30 days after it has been received by the FDA, unless the FDA otherwise informs the sponsor prior to that time that the IDE is approved,

approved with conditions, or disapproved.

A nonsignificant risk investigational device study does not require FDA approval of an IDE.

Some types of device studies, including many IVD studies, are exempt from IDE requirements altogether.

trials must be conducted in accordance with good clinical practice (“GCP”) requirements contained in federal regulations

and in international guidelines.

Clinical trials, for both significant and nonsignificant risk devices, as well as exempt studies, must

be approved by an institutional review board (“IRB”), an appropriately constituted group that has been formally designated

to review and monitor biomedical research involving human subjects and which has the authority to approve, require modifications in,

or disapprove research to protect the rights, safety, and welfare of the human research subject.

FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions, if it believes that

the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical

trial patients.

An IRB may also require the clinical trial it has approved to be halted, either temporarily or permanently, for failure

to comply with the IRB’s requirements or may impose other conditions or sanctions.

the QSR does not fully apply to investigational devices, the requirement for controls on design and development does apply.

also must manufacture the investigational device in conformity with the quality controls described in the IDE application and any conditions

of IDE approval that the FDA may impose with respect to manufacturing.

a device is placed on the market, numerous general regulatory controls apply.

These include the QSR, labeling regulations, medical device

reporting regulations (which require that manufacturers report to the FDA if their device may have caused or contributed to a death or

serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur), and

reports of corrections and removals regulations (which require manufacturers to report recalls or removals and field corrections to the

FDA if initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA).

Failure to properly identify reportable

events or to file timely reports, as well as failure to address each of the observations to the FDA’s satisfaction, can subject

a manufacturer to warning letters, recalls, or other sanctions and penalties.

marketing, and promotional activities for devices are also subject to FDA oversight and must comply with the statutory standards of the

FDCA and the FDA’s implementing regulations.

Manufacturers

of medical devices are permitted to promote products solely for the uses and indications set forth in the approved or cleared product

A number of enforcement actions have been taken against manufacturers that promote products for “off-label” uses

(i.e., uses that are not described in the approved or cleared labeling).

of the FDCA relating to inappropriate promotion of medical devices may also lead to investigations alleging violations of federal and

state healthcare fraud and abuse and other laws, as well as state consumer protection laws.

a PMA or Class II 510(k) or de novo device, the FDA also may require postmarketing testing, surveillance, or other measures to

monitor the effects of an approved or cleared product.

The FDA may place conditions on a PMA-approved device that could restrict the

distribution or use of the product.

In addition, quality control, manufacture, packaging, and labeling procedures must continue to conform

to the QSR after approval and clearance, and manufacturers are subject to periodic inspections by the FDA.

Accordingly, manufacturers

must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with the QSR and

other applicable regulatory requirements.

The FDA may withdraw product approvals or recommend or require product recalls if a company

fails to comply with regulatory requirements.

Approval Process

the U.S., therapeutic products are subject to extensive regulation by the FDA.

The FDCA and other federal and state statutes and regulations,

govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and

marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

to comply with applicable U.S.

requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical

hold, FDA refusal to approve pending new drug applications (“NDAs”), warning or untitled letters, product recalls, product

seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.

for a new therapeutic product in the U.S.

typically involves preclinical laboratory and animal tests, the submission to the FDA of an

investigational new drug application (“IND”), which must become effective before clinical testing may commence, and adequate

and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval

Satisfaction of FDA premarket approval requirements typically takes many years, and the actual time required may vary substantially

based upon the type, complexity, and novelty of the product or disease.

tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics

and potential safety and efficacy of the product.

The conduct of the preclinical tests must comply with federal regulations and requirements,

including Good Laboratory Practices.

The results of preclinical testing are submitted to the FDA as part of an IND along with other information,

including information about product chemistry, manufacturing and controls, a general investigational plan, and a proposed clinical trial

Long-term preclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the

IND is submitted.

A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing

If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND

If the IND is placed on clinical hold, the sponsor must resolve any issues to the satisfaction of the FDA before the clinical

hold is lifted and the clinical trial may proceed.

trials involve the administration of the investigational drug to healthy volunteers or patients under the supervision of a qualified

investigator.

Clinical trials must be conducted (1) in compliance with federal regulations;

(2) in compliance with GCP requirements;

and (3) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness

criteria to be evaluated.

Each protocol involving testing on U.S.

patients and subsequent protocol amendments must be submitted to the

FDA as part of the IND.

FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that

the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical

trial patients.

Imposition of a clinical hold may be full or partial.

The study protocol and informed consent information for patients

in clinical trials must also be submitted to an IRB for approval.

The IRB will also monitor the clinical trial until completed.

may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s

requirements or may impose other conditions.

Additionally, some clinical trials are overseen by an independent group of qualified experts

organized by the clinical trial sponsor, known as a data safety monitoring board or committee.

This group provides authorization for

whether a trial may move forward at designated checkpoints based on access to certain data from the trial.

trials to support NDAs for marketing authorization are typically conducted in three sequential phases, which may overlap or be combined.

In Phase 1, the initial introduction of the drug into patients, the product is tested to assess safety, dosage tolerance, metabolism,

pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect

Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular

indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks.

If a compound demonstrates evidence

of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information

about clinical effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical

trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for

the labeling of the product.

In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate

the safety and efficacy of the drug.

In rare instances, a single Phase 3 trial may be sufficient when either (1) the trial is a large,

multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on

mortality, irreversible morbidity, or prevention of a disease with a potentially serious outcome and confirmation of the result in a

second trial would be practically or ethically impossible or (2) the single trial is supported by other confirmatory evidence.

on the basis of a single trial may be subject to a requirement for additional post-approval studies.

phases may overlap or be combined.

For example, a Phase 1/2 clinical trial may contain both a dose escalation stage and a dose expansion

stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional

Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s).

Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients

and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical

trials for non-oncology therapies.

addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease

is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access

to such investigational drug.

the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress

report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to

the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk

to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and

any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator

completion of the required clinical testing, an NDA is prepared and submitted to the FDA.

FDA approval of the NDA is required before

marketing and distribution of the product may begin in the U.S.

The NDA must include the results of all preclinical, clinical, and other

testing and a compilation of data relating to the product’s pharmacology, chemistry, manufacture, and controls.

The cost of preparing

and submitting an NDA is substantial.

The submission of most NDAs is additionally subject to a substantial application user fee.

an approved NDA, the applicant is also subject to an annual program fee.

These fees typically increase annually.

The FDA has 60 days

from its receipt of an NDA to determine whether the application will be filed based on the FDA’s determination that it is adequately

organized and sufficiently complete to permit substantive review.

Once the submission is filed, the FDA begins an in-depth review.

FDA has agreed to certain performance goals to complete the review of NDAs.

Most applications are classified as Standard Review products

that are reviewed within ten months of the date the FDA files the NDA;

applications classified as Priority Review are reviewed within

six months of the date the FDA files the NDA.

An NDA can be classified for Priority Review when the FDA determines the drug has the potential

to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared

to available therapies.

The review process for both standard and priority reviews may be extended by the FDA for three or more additional

months to consider certain late-submitted information, or information intended to clarify information already provided in the NDA submission.

FDA may also refer applications for novel products, as well as products that present difficult questions of safety or efficacy, to be

reviewed by an advisory committee – typically a panel that includes clinicians, statisticians and other experts – for review,

evaluation, and a recommendation as to whether the NDA should be approved.

The FDA is not bound by the recommendation of an advisory

committee, but generally follows such recommendations.

Before approving an NDA, the FDA will typically inspect one or more clinical sites

to assure compliance with GCP.

Additionally, the FDA will inspect the facility or the facilities at which the drug product is manufactured.

The FDA will not approve the product unless compliance with current good manufacturing practices (“cGMP”) is satisfactory.

After the FDA evaluates the NDA and completes any clinical and manufacturing site inspections, it issues either an approval letter or

a complete response letter.

A complete response letter generally outlines the deficiencies in the NDA submission and may require substantial

additional testing or information in order for the FDA to reconsider the application for approval.

If, or when, those deficiencies have

been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.

The FDA has committed

to reviewing such resubmissions in two or six months depending on the type of information included.

An approval letter authorizes commercial

marketing and distribution of the drug with specific prescribing information for specific indications.

As a condition of NDA approval,

the FDA may require a risk evaluation and mitigation strategy (“REMS”) to help ensure that the benefits of the drug outweigh

the potential risks to patients.

A REMS can include medication guides, communication plans for healthcare professionals, and elements

to assure a product’s safe use (“ETASU”).

ETASU can include, but are not limited to, special training or certification

for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of

patient-specific registries.

The requirement for a REMS can materially affect the potential market and profitability of the product.

Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product’s safety or efficacy.

granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following

initial marketing.

Changes to some of the conditions established in an approved NDA, including changes in indications, product labeling,

manufacturing processes, or facilities, require submission and FDA approval of a new NDA, or a supplement to an approved NDA, before

the change can be implemented.

An NDA supplement for a new indication typically requires clinical data similar to that in the original

application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing original NDAs.

of Clinical Trial Information

of clinical trials of FDA-regulated products, including diagnostic and drugs products, are required to register and disclose certain

clinical trial information on the website www.clinicaltrials.gov.

Information related to the product, patient population, phase of investigation,

trial sites, and investigators, and other aspects of a clinical trial are then made public as part of the registration.

also obligated to disclose the results of their clinical trials after completion.

Disclosure of the results of clinical trials can be

delayed in certain circumstances for up to two years after the date of completion of the trial.

Competitors may use this publicly available

information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.

Post-Approval

an NDA is approved, a product will be subject to certain post-approval requirements.

For instance, the FDA closely regulates the post-approval

marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored

scientific and educational activities, and promotional activities involving the internet.

A drug may be marketed only for the approved

indications and in accordance with the provisions of the approved labeling.

event reporting and submission of periodic safety summary reports is required following FDA approval of an NDA.

The FDA also may require

postmarket testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place

conditions on an approval that could restrict the distribution or use of the product.

In addition, quality control, product manufacture,

packaging, and labeling procedures must continue to conform to cGMP after approval.

Drug manufacturers and certain of their subcontractors

are required to register their establishments with the FDA and certain state agencies.

with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a drug product’s

manufacturing facilities to assess compliance with cGMP.

Accordingly, manufacturers must continue to expend time, money, and effort in

the areas of production and quality control to maintain compliance with cGMP.

Regulatory authorities may withdraw product approvals or

request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial

marketing, or if previously unrecognized problems are subsequently discovered.

medical device or diagnostic test must be CE marked to be sold in the EU.

The In Vitro Diagnostic Device Regulation (“IVDR”)

of the EU defines the necessary pre-conditions that must be fulfilled to CE mark an IVD test or in vitro medical device in the EU.

manufacture of the test and/or device must fulfill all applicable regulatory requirements in the IVDR.

Objective evidence of fulfilment

of these requirements must be provided by the manufacturer prior to placing a test on the EU market.

The manufacturer is required to

establish a Quality Management System (“QMS”) as well as processes for manufacturing, importing, distribution, post-market

surveillance, and vigilance.

Regulations also require that the product is fully documented.

In addition, it is likely that our CyPath ®

Lung test is classified in a risk class that requires a review by an external party, a Notified Body, prior to placing the test

on the EU market.

This process is expected to require an additional six to 12 months after required documents and systems are in place.

There currently is a general shortage in the EU of available Notified Bodies designated for IVDR devices.

Further, we will need to contract

a European Authorized Representative (“EAR”) that acts as the Company’s legal representative in the EU.

Medical devices

also must be registered with the competent authority in the country in which they are based.

In addition to the CE mark and the registration

done by the EAR, there is a need for an administrative national notification with certain member states of the EU.

Data Collection

collection and use of personal data (including health data) in the European Economic Area (the “EEA”) are governed by the

EU General Data Protection Regulations (the “EU GDPR”) and national implementing legislation in EEA member states.

GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection

with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA.

EU GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the

validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact

assessments for “high risk” processing, limitations on retention of personal data, special provisions for “special

categories of personal data” including health and genetic information of data subjects, mandatory data breach notification (in

certain circumstances), “privacy by design” requirements, and direct obligations on service providers acting as processors.

The EU GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a

country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place.

to comply with the requirements of the EU GDPR and the related national data protection laws of the EEA states may result in fines up

to 20 million euros or 4% of a company’s global annual revenues for the preceding financial year, whichever is higher.

the EU GDPR affords various data protection rights to individuals (i.e., the right to erasure of personal data) in certain circumstances,

and the ability for data subjects to claim material and non-material damages resulting from infringements of the EU GDPR.

Given the breadth

and depth of changes in data protection obligations, maintaining compliance with the EU GDPR will require significant time, resources,

and expense, and we may be required to put in place additional mechanisms ensuring compliance with the evolving data protection rules.

This may be onerous and adversely affect our business, financial condition, results of operations, and prospects.

of the World Regulation

other countries outside of the EU (or in some cases, EEA) and the U.S., such as China, Southeast Asia, and Australia, the requirements

governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country.

Additionally, the

clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements, and the ethical principles

that have their origin in the Declaration of Helsinki.

we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal

of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.

We employ 75 employees at the time of this filing, 22 employed by bioAffinity

and 53 employed by PPLS.

place significant emphasis on the recruitment, development, and retention of our employees who include award-winning scientists dedicated

to advancing scientific discovery from bench to bedside.

Of our nine employees engaged in research and development, all of whom are employed

full-time, one holds an M.D.

and six hold Ph.Ds in biology or medicinal chemistry.

Of the 53 employees at PPLS, nearly half have worked

at our clinical laboratory for more than five years.

Executive Vice President and Chief Medical and Science Officer, Vivienne Rebel, holds an M.D.

Business development is led by

our Chief Operating Officer, Xavier Reveles, who has 25 years of experience as a clinical geneticist skilled in the creation and management

of CLIA clinical laboratories, coding, and CPT reimbursement valuations.

1 unchanged sentence

Pathology as a clinical specialist in cytogenetics who has successfully launched multiple diagnostics and commercial laboratories.

innovative and collaborative culture at bioAffinity is in part responsible for the high degree of retention and professional advancement.

Of those employees hired prior to 2022, most have been with the Company for more than five years of its nine-year history.

Outside partnerships

and collaborations that advance business and scientific research are encouraged, allowing the Company to multiply workforce efforts without

expending significant capital.

have recently attracted experienced salespeople with a proven record in the pulmonary field.

In November 2023, we hired Dallas Coleman

as National Sales Director who has more than 15 years of experience in medical sales and marketing, most recently as Executive Account

Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division.

In February 2024, Cole Koeppen joined

us as Pulmonary Sales Executive for CyPath ® Lung in North Texas.

Previously, he was Territory Sales Associate for Pulmonx

Corporation, a provider of treatments for patients with COPD.

Our innovative and collaborative culture is in part responsible for our

ability to attract and retain highly skilled professionals seeking professional advancement.

Outside partnerships and collaborations

that advance business and scientific research are encouraged, allowing us to multiply workforce efforts without expending significant

of Being an Emerging Growth Company and a Smaller Reporting Company

qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act.

as long as we remain an emerging growth company, we may take advantage of specified reduced reporting requirements and other burdens

that are otherwise applicable generally to other public companies.

These provisions include, but are not limited to:

obligations with respect to financial data, including presenting only two years of audited

financial statements and selected financial data, and only two years of related Management’s

Discussion and Analysis of Financial Condition and Results of Operations disclosure in our

initial registration statement;

exemption from the auditor attestation requirement in the assessment of our internal control

over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended (“SOX”);

disclosure about executive compensation arrangements in our periodic reports, registration

statements, and proxy statements;

from the requirements to seek non-binding advisory votes on executive compensation or stockholder

approval of any golden parachute arrangements.

may take advantage of some or all of these provisions until we are no longer an emerging growth company.

We will remain an emerging growth

company until the earliest of (1) the last day of the fiscal year following the fifth anniversary of the completion of our initial public

offering, (2) the last day of the first fiscal year in which our annual gross revenues exceed $1.235 billion, (3) the date on which we

have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities and (4) the

date on which we are deemed to be a large accelerated filer under the rules of the SEC.

We may choose to take advantage of some but not

all of these reduced burdens.

For example, we have taken advantage of the reduced reporting requirements with respect to disclosure regarding

our executive compensation arrangements, have presented only two years of audited financial statements and only two years of related

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in this Annual Report,

and have taken advantage of the exemption from auditor attestation on the effectiveness of our internal control over financial reporting.

To the extent that we take advantage of these reduced burdens, the information that we provide stockholders may be different than you

might obtain from other public companies in which you hold equity interests.

addition, the JOBS Act permits emerging growth companies to take advantage of an extended transition period to comply with new or revised

accounting standards applicable to public companies.

We have elected to use this extended transition period.

As a result of this election,

our timeline to comply with new or revised accounting standards will in many cases be delayed as compared to other public companies that

are not eligible to take advantage of this election or have not made this election.

Therefore, our financial statements may not be comparable

to those of companies that comply with the public company effective dates for these accounting standards.

are also a “smaller reporting company” as defined in the Securities Exchange Act of 1934, as amended, (“the Exchange

Act”) and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies.

extent that we continue to qualify as a “smaller reporting company” as such term is defined in Rule 12b-2 under the Exchange

Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an “emerging growth

company” may continue to be available to us as a “smaller reporting company,” including exemption from compliance with

the auditor attestation requirements pursuant to SOX and reduced disclosure about our executive compensation arrangements.

We will continue

to be a “smaller reporting company” until we have $250 million or more in public float (based on our Common Stock) measured

as of the last business day of our most recently completed second fiscal quarter or in the event we have no public float (based on our

Common Stock) or a public float (based on our Common Stock) that is less than $700 million, annual revenues of $100 million or more during

the most recently completed fiscal year.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business